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Abstract
The growing population of cancer survivors at risk of radiation induced side-effects
is a public health concern. These side-effects include serious conditions such as second
cancers, the majority of which occur outside of the primary treatment volume. Radiotherapy
treatment planning systems systematically underestimate the dose to tissues out-of-field.
Attempts to predict and reduce the risks of radiogenic side effects require accurate and
personalized knowledge of the out-of-field radiation dose to patients. The long-term goal
of this research is to provide clinical and research tools necessary to reduce the risk of
radiotherapy side effects and improve the health outcomes of radiotherapy patients. The
goal of this dissertation was to characterize the stray radiation from external beam radiation
therapy, including megavoltage x-ray therapy and proton therapy.
Chapter 1 gives a brief primer on radiation therapy and a summary of the state of
knowledge regarding stray radiation exposures. In Chapter 2, we developed an analytical
model of leakage neutron exposures from passively scattered proton therapy based on Monte
Carlo simulations and measurements from two proton therapy facilities. Predicted neutron
equivalent doses agreed with simulations and measurement to within 15%. In Chapter 3,
we developed a broadly applicable model of stray photon radiation from conventional x-ray
therapy. Predicted doses agreed with corresponding measurements to within 10% for two
treatment machines and five photon beam energies. In Chapter 4, we report measurements,
simulations, and a physics-based analytical model of stray photon radiation that realistically
models transmission through complex collimator shapes. A gamma index analysis comparing
predicted and measured doses found an 89.3% passing rate for criteria of 3-mm distance-toagreement, 3% dose difference in-field, and 3-mGy/Gy dose difference out-of-field. Chapter 5
presents a model of photoneutron exposures from x-ray radiotherapy. Predicted absorbed
doses agreed with simulations within 10%. In Chapter 6, we describe the simulation of
external and internal neutron radiation from a compact proton therapy facility. External
neutrons were the greatest source of dose out-of-field, but internal neutron dose was greater

xii

than external neutron dose near the field-edge. Chapter 7 summarizes the results presented
in this dissertation. Our major finding is that fast, accurate analytical models of stray
radiation dose are feasible.
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Chapter 1.
Introduction
1.1. External Beam Radiation Therapy
Radiation therapy, also know as radiotherapy, is a medical therapy that utilizes
ionizing radiation for the purpose of treating disease, including arteriovenous malformation
(AVM), trigeminal neuralgia, and, most commonly, cancer. Research into the therapeutic
use of ionizing radiation began shortly after the discovery of x-rays by Wilhelm Röntgen
in 1895 [1]. Along with surgery and chemotherapy, radiation therapy forms the triad of
therapies at the center of modern cancer treatment. External beam radiation therapy is
the most common form of radiation therapy and makes use of an external radiation source
directed at the area of the patient to be treated [2]. Importantly, external beam radiation
therapy can further classified into subtypes based on the type and energy of radiation
employed.
1.2. Megavoltage X-Ray Radiation Therapy
The most common form of external beam radiation therapy is megavoltage x-ray
therapy and is delivered via electron linear accelerators, commonly referred to as linacs.
X-ray photons are generated by impinging a narrow beam of high-energy electrons onto
a target made of a high-Z material such as tungsten. The term megavoltage refers to the
potential difference experienced by the electrons as they pass through the linac. Typical
accelerating potentials range from 4- to 25-MV.
The process by which high-energy electrons incident on a target produce x-rays is
known as bremsstrahlung, which comes from the German for “braking radiation.” When
a negatively charged electron passes near the positively charged nucleus of atom in the
target material, the attraction causes the electron to be deflected from its initial path and
to lose energy. A bremsstrahlung photon is emitted with an energy equal to the energy
lost by the electron such that energy and momentum are conserved. An illustration of the
bremsstrahlung process is shown in Figure 1.1. When a beam of megavoltage electrons
1

Ef

hν = Ei − Ef
Ei
Figure 1.1. Illustration of bremsstrahlung. An incident electron of energy Ei passes near a
target nucleus. The electron loses kinetic energy, and its path curves toward the nucleus.
The electron emits a photon of energy hν = Ei − Ef , where Ef is the final energy of the
electron, ν is the frequency of the emitted photon, and h is Planck’s constant.
is incident upon a target of thickness similar to the stopping length of the electrons, the
resulting beam of photons is forward peaked, but broad, with a continuous energy spectrum
of photons between zero and the maximum energy of the incident electrons. As a rule of
thumb, the mean energy of the resulting x-ray beam will be approximately one-third the
energy of the electron beam [3].
The goal of radiation therapy is to deliver conformal dose of radiation to the target
volume while sparing normal tissue as much as possible, and so it is necessary to shape the
broad beam of x-rays produced in the target. Figure 1.2 shows a simplified, 2-dimensional
drawing of the linac head components that shape and monitor the x-ray beam. After the
bremsstrahlung field is produced in the target, the conical aperture of the primary collimator
limits the maximum possible dimensions of the primary treatment field. A filter is designed
to preferentially attenuate those photons on and near the central-axis, where the beam’s
fluence peaks, in order to create a laterally flat dose distribution at a depth of 10 cm in
water. Transmission monitor chambers are used to monitor to the dose rate and total
dose delivered to ensure the machine output is as expected and is designed to minimize its
perturbation of the radiation field. Secondary collimators provide the final collimation of
the field to the desired size and shape. Modern radiotherapy linacs have separate secondary
2
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Figure 1.2. Simplified illustration of a megavoltage x-ray therapy beam setup. Important
components of the linac head for producing and shaping the treatment field are labeled.
The shaded region represents the x-ray field.
collimators that travel along orthogonal axes. These are commonly referred to as x- and
y-axis collimators. However, it should be noted that the secondary collimator structure can
rotate about the beam’s central axis, and so the x- and y-axes in the collimator frame may
not coincide with those of the patient frame.
While Figure 1.2 depicts an ideal case in which no radiation reaches the patient
outside of the treatment field, in practice, it is never possible to stop all stray radiation.
The result is that the patient’s healthy tissues receive a “radiation bath” of doses that are
on the order of grays for tissues very near the target volume and centigray to milligray for
the most distant tissues [4, 5]. Nearly all of this stray radiation dose is deposited by four
main sources: leakage, head-scatter, patient-scatter, and photoneutron contamination [6].
These sources are described below and illustrated in Figure 1.3.
Leakage radiation exposure occurs because a fraction of the primary x-rays incident
on the collimators and other beam limiting devices in the head will escape without being
attenuated [6]. The International Electrotechnical Commission mandates that the absorbed
dose rate due to radiation, excluding neutrons, emanating from the head shielding of a
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Figure 1.3. Illustration of the different sources of stray radiation.
medical linac be limited to a maximum of not more than 0.2% and an average of not more
than 0.1% of the absorbed dose rate on the central-axis of a 10×10 cm2 field [7]. Another
consequence is that the leakage spectrum will be significantly hardened and have an average
energy greater than that of the primary field.
Scattered x-rays are another important source of stray radiation [8, 9]. This is
because, for photon beams in the clinical range of beam energies, Compton scattering is
the most likely mechanism of interaction in matter [3]. Photons generated by scattering
events in the components of the linac head are classified as head scatter, and those photons
that scatter inside the patient or phantom are known as patient scatter. Since a scattered
photon will be lower in energy than the incident photon, head- and patient-scatter radiation
will be of lower average energy than the primary beam.
Another important source of stray radiation from megavoltage x-ray therapy is
photoneutron contamination [10, 11]. Neutron contamination of clinical photon beams
results primarily from photons undergoing nuclear reactions (γ, n) with the nuclei of
high-Z atoms in the treatment head. Electroneutron (e, e0 n) interactions can also be a
source of neutron contamination, but these interactions are less likely than photoneutron
interactions by around two orders of magnitude [12]. The primary mechanism of interaction
for photoneutron production is the giant dipole resonance [13]. The giant dipole resonance
4

can be described as a collective excitation of the nucleus in which the protons oscillate
against the neutrons [14]. The nucleus can then relax via the emission of one or more
particle types including protons (γ, p), deuterons (γ, d), alphas (γ, α), and neutrons (γ, n);
however, the ranges of any charged particles emitted will typically be below 1 mm, and
so only the neutrons are dosimetrically important [15]. While the absorbed dose from
photoneutron contamination is less than that from stray-photons in all cases, there is a large
uncertainty in neutron relative biological effectiveness. NCRP Report No. 116 recommends
a quality factor of 20 for neutrons in the range of energies produced by medical linacs, and
so their contribution to equivalent dose is not negligible [16].
Unlike the other sources of stray radiation, the production of neutrons by incident
photons exhibits a threshold energy. In order to liberate a neutron from the nucleus of an
atom, the photon energy must be greater than the neutron separation energy. This can
be thought of as the binding energy of the “last” neutron in the nucleus. The neutron
separation energy, Sn , of an isotope, A
Z X, can be calculated as

MA−1 X + Mn − MAZ X = Sn

(1.1)

Z

where Mn is the neutron mass, MAZ X is the isotopic mass, and MA−1 X is the mass of the
Z

isotope with one fewer neutrons. Linac collimators and other head components are primary
comprised of lead and tungsten. The lowest neutron separation energy of the naturally
occurring isotopes of these elements is 6.2 MeV for tungsten-183. Because of this, it is
often stated that photoneutron contamination only occurs for photon-beam energies ≥ 10
MV. However, some modern linacs come equipped with exit windows at the end of the
primary collimator made of beryllium-9 typically located at the primary collimator exit,
which has the lowest neutron separation energy of any stable isotope at 1.67 MeV. As
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Figure 1.4. ENDF/B-VII photoneutron production cross-sections versus photon energy for
Tungsten-183 and Beryllium-9 [18].
this is less than the average energy of photons in a 6-MV beam, there is the potential for
neutron contamination [17]. The ENDF/B-VII photoneutron production cross-sections for
tungsten-183 and beryllium-9 are shown in Figure 1.4.
1.3. Proton Therapy
Proton therapy is an emerging form of external beam radiation therapy that is
becoming commonplace [19]. As of this writing, there are 31 proton centers in operation in
the United States, more than half of which have existed for less than five years. At least 13
more are in various stages of planning and construction [20]. The primary motivation behind
the expansion of proton therapy is its ability to deliver conformal dose distributions to
target volumes while delivering a lower integral dose to the patient’s healthy tissues [21–24].
This is possible because, as massive charged particles, protons have a finite range in matter
leading to near zero absorbed dose to tissues distal to the Bragg peak. Another consequence
of this feature of charged particles is that, by designing collimators with thickness greater
than the range of the primary protons, one can ensure that no primary protons may leak
through the beam limiting devices of the treatment head.
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Clinical proton beams are generated by cyclotrons or synchrotrons. Synchrotrons
have the capability to select the energy of the output beam to suit the range needs of
a particular treatment, but the majority of new proton centers are based on cyclotron
accelerators due to their smaller footprint and lower cost compared to synchrotrons. The
output energy of a cyclotron is typically fixed based on the cyclotron radius and strength of
the static magnetic field, and so the proton energy must be degraded to the desired value
at some point downstream in the beam-line.
The protons extracted from the accelerator are arranged in a narrow beam. There
are two methods of distributing the protons to irradiate the lateral extent of a target.
In passively-scattered proton therapy (PSPT), this is accomplished via the inclusion of
scattering foils [24–26]. Multiple coulomb scattering in the scattering foils spread the beam
laterally. Scanned-beam proton therapy (SBPT) machines make use of scanning magnets
to deflect the proton pencil beam as it exits the head [24, 27, 28]. In this way, a broad dose
distribution can be obtained by delivering many discrete spot beams, either one at a time
or by sweeping the beam across the target [29]. An advantage of SBPT is that collimators
are not necessary to shape the field. However, scanned beams delivered without collimators
typically result in a broader penumbra (i.e., lateral distance between the 80% and 20%
isodose lines) than passive-scatter for depths . 15 cm [30]. Scanned-beam treatments
delivered with collimators show improved penumbrae [31–33].
While the ability to deliver treatments with lower dose to the patient’s healthy tissues
is an advantage of proton therapy over megavoltage x-ray therapy, there are still multiple
sources of stray radiation exposure to the patient that must be considered. As previously
mentioned, the leakage of primary charged particles through the treatment head shielding
is not a concern for proton therapy, but primary protons may still scatter off of the edges of
collimators and other beam-limited devices. These so called “edge scattered photons” can
degrade the lateral penumbrae of the field and deposit stray dose in the healthy tissues
surrounding the tumor volume [34, 35].
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Figure 1.5. Illustration of the Bertini model of the intranuclear cascade process. The label
p indicates a proton, n indicates a neutron, and the cluster of particles with two protons
and two neutrons represents an α.
The largest concern regarding stray radiation in proton therapy is exposure to
secondary particles, especially neutrons [36, 37]. Secondary neutrons, and other secondary
particles, are produced by nuclear interactions between an incident proton and an atomic
nucleus. These interactions occur both in the treatment head and in the patient or phantom
[24]. Unlike x-ray therapy, all of the primary particles in a clinical proton beam have
energies far greater than the average binding energy per nucleon of even the most stable
isotopes. The nuclear reaction undergone by a high energy proton incident upon a nucleus
was modeled by Bertini as an intranuclear cascade in which the nucleons are treated as free
particles. The proton causes a cascade of scattering events that result in multiple particles
being ejected from one or more nuclei as illustrated in Figure 1.5 [38]. The velocities of
the ejected cascade particles are forward peaked and can have energies up to that of the
incident proton. After the cascade, the atomic nucleus is then left in an excited state and
can relax via the emission of evaporation neutrons (or other particles) that are lower in
energy and are emitted isotropically.
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Figure 1.6. Typical neutron spectrum at isocenter for a 250-MeV proton beam produced
via the passive scattering technique.
The energy spectrum of neutrons produced by a clinical proton beam can be divided
into four regions, as show by the plot of a typical spectrum in Figure 1.6. The two peaks
at the upper end of the energy spectrum are comprised of the cascade and evaporation
neutrons described above. There is a continuum of neutrons at the middle energies that
have been partially thermalized. These are known as epithermal or 1/E neutrons in the
literature. Finally, there is a low energy peak of thermal neutrons that will be centered
around 2.5 × 10−8 MeV assuming room temperature conditions.
1.4. Motivation and Purpose
Approximately 50% of individuals will be diagnosed with cancer at some point in
life [39], and in developed nations, around two-thirds of cancer patients receive radiation
therapy as part of their care [40]. Improvements in cancer detection and care have led to
steadily improving five-year survival rates in recent decades, surpassing 70% in adults and
80% in children [39, 41]. With the population of cancer survivors living in the United States
expected to surpass 20 million by the year 2026, the need to understand and mitigate the
side effects of cancer treatment is a pressing public health concern.
Cancer survivors face an increased risk of conditions including cardiac toxicity,
fertility complications, and radiogenic second cancers to name just a few [5]. Cancer
survivors who received radiation therapy as part of their care are twice as likely to develop
9

a second cancer compared with those who did not [42]. Diallo et al. [43] reports that, for a
cohort of radiation therapy patients who presented with second cancers years after initial
treatment, the vast majority occurred in tissues outside of the treatment volume, with 30%
occurring in tissues receiving less than 2.5 Gy. In spite of this, treatment planning systems
systematically underestimate the dose out of field for both x-ray and proton treatments
[44–48]. To remedy this, fast and accurate methods of calculating stray radiation dose are
required.
As discussed in Sections 1.1–1.3, all forms of radiation therapy result in low doses to
the patient’s healthy tissues. Attempts to characterize these doses in the literature have
typically followed some combination of three approaches; measurements [6, 49–51], Monte
Carlo simulations [9, 52–54], and empirical parameterizations [55–59]. Measurements are a
necessary first step to ensure attempts to characterize stray radiation are grounded in reality,
but high quality measurements of low doses such as those found out of field are difficult
to perform, require expensive equipment, and are too time consuming to be practical for
routine, patient specific purposes. Monte Carlo simulations are also time consuming and
computationally expensive, especially since acquiring good statistics far from the treatment
field requires many more particle histories than are needed for locations in field.
Previous work from our research group has demonstrated the feasibility of using
physics-based analytical models to calculate the stray radiation dose [47, 60]. The specific
purpose of this dissertation has been to develop such models for the most common forms of
external beam radiation therapy. Chapter 2 describes an analytical model of the external
neutron dose from passively-scattered proton therapy. Chapter 3 describes a simplified
model of stray radiation dose from external beam photon radiotherapy developed to test
the feasibility of a simple model to calculate stray dose from multiple treatment machines.
Chapter 4 describes a detailed, physics-based analytical model of stray radiation dose
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from 6-MV beams delivered with an Elekta linac. Chapter 5 reports on a model of the
photoneutron absorbed dose from 6–25 MV x-ray beams. Finally, Chapter 6 reports a
Monte Carlo model of the internal neutron dose from to PSPT and SBPT.
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Chapter 2.
An Analytical Model of Leakage Neutron Equivalent Dose for
Passively-Scattered Proton Radiotherapy and Validation with Measurements
2.1. Introduction
In many cases, proton therapy is dosimetrically advantageous compared to other
forms of external beam radiation therapy because it allows for uniform target coverage with
lower doses to healthy tissues [1–3]. However, proton therapy patients are still exposed to
stray radiation, which is not fully understood and not routinely estimated for most patients.
Most proton beam treatments are delivered by the passive scattering technique. Stray
radiation dose to the patient from passively scattered proton therapy (PSPT) primarily
comes from neutrons that leak out of the treatment head [4, 5]. This is a concern because
neutrons have an enhanced relative biological effectiveness compared with protons [6, 7],
and even relatively small doses far from the primary treatment field increase the risk of
secondary cancers [8]. Commercial treatment planning systems do not take neutron dose
into account. Researchers have relied mainly on measurements and Monte Carlo-based
simulation in order to learn more about neutron exposures. However, the time required for
these methods is a barrier to research and routine clinical use. Thus, there is a need for
fast, accurate analytical models of leakage neutron equivalent dose from proton therapy.
Polf and Newhauser [9] reported that analytical models of neutron equivalent dose
from proton therapy are feasible. One proposed analytical model employed a power law to
predict neutron equivalent dose per therapeutic dose (H/D) for passively scattered proton
therapy for different field sizes and locations within a treatment vault [10, 11]. This model
was refined for 250 MeV pristine proton beams, both in-air and in a water phantom, by
Zhang et al. [12]. Anferov [13] reported a model based on shielding calculation methods to
predict the equivalent dose from neutrons for 100, 150, and 200 MeV proton beams.
Adapted with permission from: Schneider, C.; Newhauser, W.; Farah, J., An Analytical Model
of Leakage Neutron Equivalent Dose for Passively-Scattered Proton Radiotherapy and Validation with
Measurements. Cancers. 2015, 7, 795–810. Copyright (2015) MDPI AG (Basel, Switzerland).
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The most compete and realistic leakage model to date was reported by PerezAndujar et al. [14], which takes into account four separate neutron energy regimes to predict
H/D in-air and in-water for proton beams with energies between 100 and 250 MeV. The
model was found to have good agreement when compared with benchmarked Monte Carlo
simulations. However, this model was not continuous with proton beam-energy and required
interpolation of parameters between the discrete energies considered. The model’s large
number of parameters made its configuration and use difficult. Furthermore, the model was
not compared with measured data nor was it tested at proton beam energies below 100
MeV.
The purpose of this study was to improve an analytical model of neutron H/D by
making it continuous in energy and reducing the number of free parameters, thus simplifying
its configuration and use. We compared the results of this model with Monte Carlo simulated
neutron H/D values between 100 and 250 MeV for a conventional proton therapy beam-line.
Additionally, we configured and tested a version of the model with new H/D measurements
at 75 MeV proton beam energy.
2.2. Methods
2.2.1. Analytical Model
Building upon the methods of Perez-Andujar et al. [14], we improved an analytical
model for (H/D) from leakage neutrons from passively scattered proton therapy. For the
reader’s convenience, we briefly review the previous model here. (H/D) contributions are
calculated from four neutron energy regimes: intranuclear cascade neutrons (also called
direct neutrons), evaporation neutrons, epithermal neutrons (also called (1/E) neutrons),
and thermal neutrons. Cascade neutrons are produced when a bombarding proton interacts
with a target nucleus and can have energies up to the maximum energy of the proton
beam. The second highest energy regime, that of evaporation neutrons, corresponds to
neutrons ejected by the excited nucleus after the initial proton collision in processes known
as compound emission and pre-equilibrium emission. The third energy regime, epithermal
17

neutrons, corresponds to neutrons that have lost some portion of their energy via inelastic
scattering and moderation. Some of these neutrons will be lost via capture processes.
Finally, the lowest energy regime corresponds to thermal neutrons that have lost most of
their kinetic energy and are in thermal equilibrium with the environment. These undergo
elastic scattering until they are eventually captured.
The analytical model for H/D at a point, p, in a water phantom is


H
D




=

p

H
D


E,iso



d
diso

−q X
4

0

Ci (E) exp [−αi (d −

d0iso )] exp

i=1




− (x2 + y 2 ) d2iso
, (2.1)
2σi2 z 2

where (H/D)E,iso is the total neutron equivalent dose per treatment dose at isocenter as
function of the proton beam energy; d is the distance from the neutron source to the
calculation point; d0 is the distance along the ray, d, from the phantom surface to the
calculation point; diso is the distance from the neutron source to isocenter; and d0iso is the
distance along the ray, diso , from the phantom surface to isocenter. The irradiation geometry,
dimensions, and distances are shown in Figure 2.1. The exponent, q, governs the power law
falloff of neutron dose with distance from isocenter. The Ci (E) terms apportion the fraction
of the total equivalent dose resulting from the each of the four neutron energy regimes. The
first exponential term models neutron attenuation in the phantom. The mean free paths of
the neutrons of the ith regime in water are denoted by αi , with the first exponential term
modeling neutron attenuation in the phantom. The second exponential term, then, models
the lateral distribution of the ith neutron regime with αi as the Gaussian width parameter.
In this work, several improvements have been made to the model. Previously, the
model required interpolation of (H/D)iso values at proton beam energies between energies
contained in the lookup tables. In this work, (H/D)E,iso has been parameterized with proton
beam energy according to a power law relationship, or


H
D


= αE × E

pE

E,iso
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Figure 2.1. Geometry of a general-purpose proton treatment head and water phantom.
Adapted from Perez-Andujar et al. [14].
where (H/D)ref,iso is the neutron equivalent dose value at isocenter for a proton beam of a
given reference energy (100 MeV in this study), pE is the exponent governing the power
law, αE is a scaling factor, and E is the proton beam energy. This value may be obtained
from measurement or from a Monte Carlo simulation and is found by taking the quotient


H
D


ref,iso

(H/p)closed
ref,iso
=
(D/p)open
ref,iso

,

(2.3)

where (D/p)open
ref,iso is the absorbed dose in gray per proton at isocenter found with the
collimator open and (H/p)closed
ref,iso is the neutron equivalent dose in sievert per proton with
the collimator closed [11].
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The previous model relied on lookup tables of 32 Ci values that were found from an
iterative fitting process; four values at each of the eight proton beam energies considered
from 100 to 250 MeV [14]. In the improved model, the Ci (E) values that apportion the
contributions from each neutron regime were parameterized as functions of proton beam
energy. Specifically, for intranuclear cascade neutrons, we use the linear form

C1 (E) = a1 E + b1

,

(2.4)

where E is the proton beam energy, a1 is the slope, and b1 is the intercept. For evaporation
neutrons, the cumulative normal was used with a lower bound as in,

C2 (E) = a2 cnorm(E, b2 , c2 ) + d2

,

(2.5)

where a2 is a scaling coefficient, d2 is the lower bound, and the cumulative normal function
with mean value b2 and width parameter c2 is defined in the usual way as
1
cnorm(E, b2 , c2 ) = √
c2 2π

E


−(E 0 − b2 )2
exp
dE 0
2
2c
−∞
2

Z



.

(2.6)

The epithermal regime was modeled as

C3 (E) = a3

,

(2.7)

where a3 is a constant. For the thermal neutrons, we used
C4 (E) = a4 E 2 + b4 E + c4

,

(2.8)

where a4 and b4 andc4 are the polynomial’s second, first, and zeroth order coefficients. Since
these curves are used to apportion the equivalent dose from each neutron energy regime,
they were constrained so that their sum is unity. The forms of Equations 2.4, 2.5, 2.7, 2.8
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and 4.37 were chosen empirically to faithfully reproduce the shapes of the C curves with
energy while simultaneously reducing the number of model parameters. Specifically, the
approach of Perez-Andujar et al. [14] required a lookup table containing 40 values plus 9
energy independent parameters for a total of 49 parameters. Our model requires only 13
values plus 9 energy independent parameters for a total of 22 parameters to cover the same
interval of proton beam energies from 100 to 250 MeV. Parameterizing these terms with
energy offers several advantages compared with the table lookup. It allows the model to
be continuous in energy and reduces the number of free parameters. The values for the
parameters αE , pE , a1 , b1 , a2 , b2 , c2 , d2 , a3 , a4 , b4 , and c4 were obtained via the iterative
fitting process described in section 2.2.4 below.
2.2.2. Monte Carlo simulated H/D values for general purpose beam-line at 100
to 250 MeV
Previous studies [12, 14] utilized dosimetric data exclusively from Monte Carlo
simulations to develop the model. In this study, we purposefully utilized the same Monte
Carlo data in order to facilitate the comparison of results with and without the improvements
developed in this work. The Monte Carlo data were taken from a simulation of the passive
scattering system in place at The University of Texas MD Anderson Cancer Center described
in detail by Perez-Andujar et al. [14]. This was accomplished with the Monte Carlo Proton
Radiotherapy Treatment Planning (MCPRTP) system [15] which utilizes the Monte Carlo NParticle eXtended (MCNPX) Radiation Transport Code [16]. MCNPX is commonly used for
simulating neutron exposures and has been extensively benchmarked against measurements
[17–22]. Simulations were carried out first with an open collimator to determine the primary
absorbed dose per proton, D/p. Next, simulations were done with a closed final collimator
to determine the neutron equivalent dose per proton, H/p, and the ratio of these yields
H/D. The simulated neutron data includes nominal proton beam energies of 100, 120,
140, 160, 180, 200, 225, and 250 MeV with a closed collimator, pristine Bragg peak, and
with the proton beam incident on a water phantom. The phantom contained 100 spherical
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detecting volumes, each of 1-cm diameter. The detecting volumes were located along lines
parallel to the beam axis at 0 cm, 10 cm, 40 cm, and 80 cm off-axis, as well as one line
perpendicular to the beam axis at the depth of isocenter in the phantom (22 cm). The
simulation geometry is illustrated in Figure 2.1.
2.2.3. Measure H/D for ocular beam-line at 75 MeV
Measurements of H/D for the 75 MeV proton beam were carried out at Centre de
Proton thérapie d’Orsay (CPO) in France in a single-scattering proton beam-line dedicated
to ocular tumor treatments. During the neutron measurements, a closed patient collimator
was used together with a pristine Bragg peak. We selected 75 MeV proton beam energy
because it is representative of ocular treatments at CPO. Measurements were taken in air.
Two instrument types were used to acquire neutron ambient dose equivalent, H ∗ (10),
in air. The Berthold LB 6411 [23] is a conventional neutron probe with a spherical
polyethylene moderator (25 cm external diameter) and a central 3He proportional counter
(4 cm external diameter and 10 cm length). It is known to be suitable for ambient dose
equivalent measurements in the energy range from thermal to 20 MeV [24]. Additionally,
this rem-counter is characterized by a high rejection coefficient for gamma radiation. The
WENDI-II is a survey meter with a cylindrical polyethylene moderator (22.9 cm in diameter
and 21 cm long), and a central cylindrical 3 He proportional counter [25]. The moderator
encloses a tungsten powder shell of 1.5 cm thickness, which enhances the accuracy of the
instrument’s response at energies above about 20 MeV by neutron multiplication.
The measurements of H ∗ (10) were made at isocenter and several distances from
isocenter along the proton beam axis and 45◦ and 90◦ with respect to the beam axis. Figure
2.2 shows the ocular beam line and the 10 measurement positions.
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Figure 2.2. Geometry of a proton therapy system for ocular treatments and positioning of
the neutron equivalent dose meters along the three axes at 0◦ , 45◦ and 90◦ with respect to
the proton beam direction.
2.2.4. Model training
Previously, the model was trained separately at each proton beam energy considered
[14]. In this work, we trained the improved model for the general purpose beam-line by
fitting to all data from 100 to 250 MeV simultaneously. All free parameters were selected
using the generalized reduced gradient method to minimize the local relative differences in
H/D [26].
The model was trained separately for the 75 MeV measurements. This was necessary
because of the considerable differences between the beam-lines. Because the measured data
from the ocular beam-line consist of a single proton beam energy and measurements were
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taken in air, some modifications were necessary. The αi terms from Equation 2.1, which
model neutron attenuation in water, were defined to be zero, since there is no water present.
The power law model for (H/D)E,iso in Equation 2.2 was simply replaced with the measured
H/D value at isocenter at 75 MeV. Finally, the Ci (E) curves defined inEquations 2.4, 2.5,
2.7, 2.8 and 4.37 were replaced with scalar coefficients C1 , C2 , C3 , and C4 .
2.3. Results
2.3.1. Model Agreement with Monte Carlo data at 100 to 250 MeV
Figure 2.3 shows the Monte Carlo simulated and analytical model calculated values
of H/D at isocenter for the general purpose and occular beam-lines. H/D along the central
axis is plotted as a function of depth in water for all energies in Figure 2.4. Figures Figures
2.5–2.7 plot the corresponding results at off-axis distances of 10 cm, 40 cm, and 80 cm,
respectively. Figure 2.8 shows lateral H/D profiles for all energies at isocenter depth (22
cm). These figures demonstrate the good agreement between the H/D values from Monte
Carlo simulations and the analytical model calculations. The average relative difference
between the analytical model and the Monte Carlo calculations at all proton beam energies
and locations considered was 10% with a maximum difference of 60%. The maximum
difference occurred for the 120 MeV proton beam energy at a location 80 cm off-axis and
19 cm deep in the phantom.
The parameters governing (H/D)E,iso from Equation 2.2 are shown in Table 2.1.
Table 2.2 lists the parameters that govern the Ci (E) curves in Equations 2.4, 2.5, 2.7, 2.8
and 4.37. Our results confirm the findings of Perez-Andujar et al. [14] that the largest
contribution to H/D is from the high-energy direct neutrons followed by the epithermal
neutrons. H/D from the evaporation neutron regime is more prevalent at higher energies,
and the thermal neutron regime contributes a relatively small component of the equivalent
dose. Figure 2.9 shows the Ci (E) curves from this work plotted with proton beam energy and
compared with analogous values from Perez-Andujar et al. [14]. Use of the parameterized
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Figure 2.3. H/Diso values versus proton beam energy, E. Ocular beam-line value (×) was
measured in air. General purpose beam-line values (◦) were obtained from Monte Carlo
simulations. Analytical model (line) values were calculated using Equation 2.2.
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Figure 2.4. Predictions from Monte Carlo (points) and analytical model (lines) of neutron
equivalent dose per treatment dose (H/D) values versus depth in water from proton beams
of 100, 120, 140, 160, 180, 200, 225, and 250 MeV.
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Figure 2.5. Predictions from Monte Carlo (points) and analytical model (lines) of neutron
equivalent dose per treatment dose (H/D) versus depth in water at 10-cm off-axis for 100
to 250-MeV proton beam energies.
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Figure 2.6. Predictions from Monte Carlo (points) and analytical model (lines) of neutron
equivalent dose per treatment dose (H/D) versus depth in water at 40-cm off-axis for 100
to 250-MeV proton beam energies.
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Figure 2.7. Predictions from Monte Carlo (points) and analytical model (lines) of neutron
equivalent dose per treatment dose (H/D) versus depth in water at 80-cm off-axis for 100
to 250-MeV proton beam energies.
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Figure 2.8. Predictions from Monte Carlo (points) and analytical model (lines) of neutron
equivalent dose per treatment dose (H/D) versus off-axis position at 22-cm depth in water
for 100 to 250 MeV proton beam energies.
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Ci (E) curves greatly reduced the difficulty of configuring the model by preventing non
physical fluctuations of several parameters with energy, eliminating the need for subjective
manual adjustments.
Table 2.1. Parameters of power law relationship for (H/D)E,iso .
αE
8.0 ×10-9

pE
4.1 ×100

(H/D)E,iso
1.2 ×10-4

Table 2.2. Parameters for Ci (E) equations to apportion equivalent dose from neutron energy
regimes.

C4 (Thermal) C3 (1/E)

C2 (Evap) C1 (Direct)

Neutron Energy Regime
Intranuclear Cascade
Evaporation
Epithermal (1/E)
Thermal

ai
-4.8 ×10-4
1.2 ×10-1
4.0 ×10-1
1.2 ×10-7

bi
6.0 ×10-1
1.3 ×102
N/A
-6.6 ×10-5

ci
N/A
5.0 ×100
N/A
1.1 ×10-2

di
N/A
-1.3 ×10-11
N/A
N/A

Perez-Andujar
This work (Refit)
This work (Final)

6.0*10-1
4.5*10-1
3.0*10-1
1.5*10-1
0
2.0*10-1
1.5*10-1
1.0*10-1
5.0*10-2
0
6.0*10-1
4.5*10-1
3.0*10-1
1.5*10-1
0
6.0*10-3
4.5*10-3
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Figure 2.9. Plot of Ci values for each neutron energy regime versus proton beam energy.
Points represent Ci values from Perez-Andujar et al. [14] (circles) and from a refitting of
that model using the improved fitting methods (squares). The solid curves represent the
parameterized Ci (E) models used in the final version.
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Table 2.3 lists the energy independent parameters, including the neutron attenuation
factors and Gaussian width parameters. As expected, the width parameters for the low
energy neutron regimes, epithermal and thermal, are very large corresponding to an isotropic
distribution. The higher energy neutron regimes are forward peaked. The exponent governing
falloff, q, was found to be 1.13. Table 2.4 lists a comparison of the accuracies for all locations
and all energies, as well as at each specific energy, between this work and Perez-Andujar
et al. [14]. We found similar agreement with the Monte Carlo simulations. The average
local relative differences were within 4% of each other for all energies. The maximum local
relative error was decreased from 76% to 60%.
Table 2.3. Neutron attenuation parameters and Gaussian width parameters for the four
neutron regimes.
Direct
α1 (cm ) σ1 (cm1 )
1.3 ×10-2 1.4 ×102
-1

Evaporation
α2 (cm-1 ) σ2 (cm1 )
1.3 ×10-2 7.7 ×101

Epithermal
α3 (cm-1 ) σ3 (cm1 )
3.2 ×10-2 3.9 ×103

Thermal
α4 (cm ) σ4 (cm1 )
3.3 ×10-1 3.9 ×103
-1

¯ and maximum local relative error (∆|max ) for
Table 2.4. Average local relative error (∆)
the analytical model of the general purpose beam-line from this work and Perez-Andujar
et al. [14].
Proton Energy
(MeV)
All
250
225
200
180
160
140
120
100

¯
∆(%)
10
7
7
7
11
11
11
11
16

This Work
∆|max (%)
60
39
29
31
31
33
45
60
54

Perez-Andujar et al. [14]
¯
∆(%)
∆|max (%)
10
76
7
30
6
29
56
34
7
34
10
45
10
46
15
61
18
76

2.3.2. Model agreement with measured data at 75 MeV
Measured and calculated H/D values for the ocular beam-line data are shown in
Figure 2.10 with separate plots for each of the rays measured along: 0◦ , 45◦ , and 90◦ with
respect to the beam axis. The plot shows good agreement between measured values and
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the analytical model. We conservatively estimated the uncertainty in the measured data at
±25%,

and the calculated H/D values agreed within this limit for all points considered. The

average error was 16% and the maximum error was 24%. The exponent that governs falloff,
q, was found to be 1.5. The larger q value is expected in this instance since the ocular
beam-line is narrower and should more closely resemble a point source. The parameters
C1 –C4 , σ1 –σ4 , and H/Diso for the ocular beam-line data are listed in Table 2.5.
Measured 0°
Calculated 0°

60
45
30
15

H/D(r) (mSv/Gy)

0

Measured 45°
Calculated 45°

60
45
30
15
0

Measured 90°
Calculated 90°

60
45
30
15
0
0

50

100

150

200

r (cm)

Figure 2.10. Measured (circles) and calculated (lines) H/D values for the ocular beam-line
plotted vs distance from isocenter. The top plot shows data taken along the beam axis with
points distal to isocenter. The middle plot shows the values along a ray 45◦ with respect to
the beam axis. The lower plot shows values directly lateral to isocenter, i.e., along a ray
90◦ with respect to the beam axis.

Table 2.5. Model parameters for ocular beam-line.
C1

C2

C3

C4

σ1
(cm)

σ2
(cm)

σ3
(cm)

σ4
(cm)

1.1×10-2 7.8×10-1 1.0×10-1 9.6×10-2 9.4×10-2 1.0×103 4.2×103 4.2×103
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(H/D)iso
(mSv/Gy)
5.2×10-5

2.4. Discussion
We have improved an analytical model for predicting H/D from leakage neutrons
for proton therapy by parameterization of energy dependent aspects of the model, thereby
reducing the number of free parameters and simplifying the model configuration process.
We have demonstrated the training of this model using Monte Carlo simulated neutron
exposures for proton beam energies from 100 to 250 MeV and using measured data from a
separate 75 MeV proton therapy beam-line.
The major finding of this work is that an analytical model of neutron H/D for
passively scattered proton therapy may be applied continuously over a wide range of proton
beam-energies with relatively few model parameters. In addition to reducing the number of
free parameters, explicitly modeling the contribution of different neutron energy regimes
based on the proton beam energy yields other advantages to our model. The model is now
continuous in energy, and this approach obviates the need to interpolate from a table of
values at intermediate energies. The model can be easily applied to energies between those
used in the work without the need for additional measurements or crude linear interpolation.
In contrast, the lookup table approach employed by Perez-Andujar et al. [14] requires the
interpolation of several parameters for use at energies other than those contained in the
lookup table and also requires a large number of energy specific parameters that complicate
the training of the model. Our method reduces the number of free parameters, and our
improved fitting methods have made the model training process much simpler for the
user. This approach gives confidence that the fitted parameters follow physically realistic
dependencies on proton beam energy and are not the result of over-fitting or memorizing
the data.
Another encouraging confirmatory finding is that the analytical model is applicable
to low energy proton beams such as those used in ocular treatments. It is important that
the model be easily adaptable to other passive scattering treatment systems, so that it can
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have the greatest possible impact and find use at many different institutions. Importantly,
Farah et al. [27] previously reported on the difficulty in configuring the original model, an
obstacle that this work has successfully overcome.
The results of this work are consistent with the findings of other studies. PerezAndujar et al. [14] found that to accurately model the equivalent dose from leakage neutrons
requires the consideration of no fewer than four neutron energy regimes. That is supported
by this work. The contributions from each of the four neutron energy regimes are similar
for this work and the previous model. Furthermore, the dosimetric accuracies were found to
be similar.
A major strength of this study is that the improved model relies on far fewer free
parameters than previous works. The inclusion of measured data from a second passivelyscattered proton therapy beam-line is another strength of this study. Specifically, the
analytical model was configured for use at the lower energy (75 MeV) and compared against
experimental data to validate its utility to predict stray radiation from an ocular beam-line.
One limitation of this study is that we only benchmarked the model with measured
data at a single proton beam energy for the ocular beam-line. Additionally, the measured
data was taken in-air and not in a water phantom. These limitations are minor because we
demonstrated good agreement for the model compared with Monte Carlo simulated H/D
values in a water phantom and at many different energies for the general purpose beam-line.
Future work on leakage radiation from proton therapy should include research
and development to translate the analytical models to clinical practice. Specifically, the
model should be integrated into treatment planning systems to facilitate routine clinical
dose assessments for patients with heterogeneous anatomy and irregular external surfaces.
A study from our group has yielded promising preliminary results indicating that the
integration of a similar analytical model into a radiotherapy treatment planning system is
technically feasible and the leakage-dose algorithm is sufficiently fast for routine clinical
treatment planning applications [28]. Specifically, this study found that the time required
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was a factor of 1.6 of the time necessary for the proton dose calculation allowing for the
total calculation to be completed in less than one hour on a single CPU. Additional research
and development work will be needed to enhance the analytical model to account for other
treatment factors such as range modulation. Range modulation can be modeled from first
principles using the proton modulation function including proton fluence weights, Eqs (2–5)
from Polf and Newhauser [9] or Eqs (1–4) from Zheng et al. [29], and dosimetric data at
multiple proton beam energies from Monte Carlo simulations. If the relationship between
H/D and the modulation width is known from measurements or simulations of the usual
case with flat-topped Bragg peaks, the dependence of H/D on modulation width may
be accounted for with an empirical analytical model. From previous work, we know that
H/D increases with modulation width modestly and continuously (see Figure 9 in Zheng
et al. [29]), and it appears to follow a simple analytic expression, e.g., a polynomial or
asymptotic exponential function. Studies on range modulation and other treatment factors
are underway in our laboratory. This model may also find application for scanned-beam
proton therapy beam-lines equipped with passive and dynamic collimators, e.g., milled
brass collimators, multi-leaf collimators [30, 31], and trimmers [32].
2.5. Conclusion
In this work, we improved an analytical model of neutron H/D for passively scattered
proton therapy in the energy range from 100 to 250 MeV. The improved model relies on
fewer configuration parameters and is easier to train. We tested the analytical model on
measured neutron H/D values from a separate 75 MeV beam-line. Our results revealed
good agreement of the model with both measured data and Monte Carlo simulations. The
results of this work suggest that, with further development and testing, analytical models
may be applicable for routine use in clinical treatment planning systems to predict neutron
exposures to patients.
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Chapter 3.
A Descriptive and Broadly Applicable Model of Therapeutic and
Stray Absorbed Dose from 6 MV to 25 MV Photon Beams
3.1. Introduction
The goal of modern external beam radiotherapy is to deliver a highly targeted
radiation dose to a diseased anatomic location or region while sparing the the rest of the
body. However, in practice, the whole body is unavoidably exposed to unwanted stray
radiation. Healthy tissue in the margin of the treatment field will receive absorbed doses
on the order of the prescribed dose. Tissues outside the treatment field receive stray dose
from scattered and leakage radiation that is one to four orders of magnitude smaller [1].
Historically, clinical practices focused almost exclusively on in-field exposures because of
their prime importance to curing primary cancers. In recent years, 5-year survival rates
have supassed 69% for all cancers [2] and 80% for childhood cancers [3], but a myriad
of radiation epidemiology studies have revealed the high prevalence of radiation-induced
late effects including cardiac toxicity and radiogenic second cancers[4, 5]. Most radiogenic
second cancers occur outside the therapeutic radiation field [6–10]. For these reasons, there
is increasing interest in knowing the small stray radiation exposures to the whole body.
Many researchers have reported algorithms to model absorbed dose from external
beam photon radiation therapy [11–14]. In general, these algorithms accurately predict
exposures inside and immediately outside the high-dose treatment field. However, none of
these algorithms have fully addressed the stray dose far from the treatment field. Stovall et
al. described three main sources of stray radiation from external beam radiation therapy
delivered with electron linear accelerators [15]. Radiation scattered from the treatment
head, known as head scatter, is primarily important within about 10 cm from the field
edge. Patient scatter is an important source up to around 30 cm from the field edge.
Adapted with permission from: Schneider, C.W.; Newhauser, W.D.; Wilson, L.J.; Schneider, U.;
Kaderka, R.; Miljanić, S.; Knežević, Ž.; Stolarcyzk, L.; Durante, M.; Harrison, R.M., A descriptive and
broadly applicable model of therapeutic and stray absorbed dose from 6 MV to 25 MV photon beams. Med
Phys. 2017, 44, 3805–3814. Copyright (2017) American Association of Physicists in Medicine.
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Finally, leakage radiation emanates from the treatment enclosure and predominates the
stray radiation dose beyond about 30 cm. Monte Carlo simulations have been a useful
research tool for modeling stray dose [16–18], but these methods have not found use in
clinical settings due to their complexity and long computational times. The feasibility
of analytical models to predict stray dose from radiation therapy has been supported by
several works [7, 19–25], but few attempts have been made at developing models accurate
for both in-field and out-of-field doses. Jagetic and Newhauser reported on one such model
that accurately predicts absorbed dose from therapeutic, scatter, and leakage radiation
[26]. This model was evaluated only at 6 MV photon-beam energy, only for Conformal
Radiation Therapy (CRT), and only for one type of electron linear accelerator (Elekta, SL25,
Stockholm). The study left open important questions. Firstly, is this approach extensible to
other treatment techniques, e.g., Intensity Modulated Radiation Therapy (IMRT)? Secondly,
is it adaptable to treatment units from other manufacturers? Third, can it be done without
proprietary data?
The objective of this study was to determine whether a physics-based analytical
modeling approach is applicable to a variety of treatment techniques and treatment units.
More specifically, we characterized the dosimetric accuracy that can be achieved without
the use of proprietary and machine-specific parameters to configure the model. In order to
accomplish this, we developed a new analytical model that can be configured with measured
dose profiles that are similar to those used for configuring commercial treatment planning
systems. The model was tested using measured data from a variety of treatment machines
and techniques in the 6 to 25 MV interval of photon beam energy.
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3.2. Methods and Materials
3.2.1. Analytical Model
The analytical model consists of four terms: one to model the therapeutic radiation
dose and three to model sources of stray dose, or

DT = DP + DHS + DPS + DL

,

(3.1)

where DT is the total dose from all sources, DP is the primary dose term that models the
therapeutic dose, DHS is the first stray dose term that models dose from head scattered
radiation, DPS is the second stray dose term that models dose from patient scattered
radiation, and DL is the third stray dose term that models leakage radiation.
Consequently, simplicity and ease of use were of prime importance to the model’s
design. In particular, we designed it for ease and simplicity of configuration, e.g., by using
non-proprietary data that can be quickly measured in most clinics. The model proposed in
this work shares the major underlying physics and mathematical form as that of Jagetic
and Newhauser, but it was radically simplified here to streamline the configuration process
and to eliminate the use of proprietary data. As will become readily apparent later, these
two features were of prime importance in configuring the model for multiple treatment
techniques and machines. Table 3.1 compares the two models and detailed descriptions of
the terms from this work follow below.
The primary absorbed dose, DP , for square and rectangular fields is given by

DP = AP × C(x, z) × C(y, z) × T FP,w (x, y, z, E)
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(3.2)

Table 3.1. Comparison of model terms for Jagetic and Newhauser [26] and this work.

Term
Uncollimated
Fluence, Φ

Jagetic and Newhauser [26]
Description
Eqn.
Modeled using
electron radiation
yield, 3 Gaussian
(2.8)
source terms, and
divergence.

This Work
Description

Eqn.

Not modeled.

N/A

(2.10)

Implicitly modeled.

(3.2)

(3.2)

(3.18)

In-air
Primary
Collimated
Fluence, ΦP

Uncollimated fluence
multiplied by
cumulative normal.

Primary Dose
in Water,
DP,w

In-air primary fluence
multiplied by
transmission factor
and mass-energy
absorption coefficent.

(2.15)

Cumulative normal
multiplied by
transmission factor
and primary scaling
factor.

Leakage
Fluence, ΦL

Uncollimated fluence
multiplied by
complimentary
cumulative normal.

(2.17)

Implicitly modeled.

Leakage Dose
in Water,
DL,w

Leakage fluence
multiplied by
transmission factors
(2.20)
for collimators and
water and mass-energy
absorption coefficient.

Cumulative normal
multiplied by
Gaussian source term,
water transmission
(3.18)
factors, and energy
dependent leakage
scaling factor.

Head-Scatter
Dose in
Water, DHS,w

Gaussian multiplied
by empirical, field-size
dependent, scaling
factor and water
transmission factor.

(2.27)

Gaussian multiplied
by energy-dependent
scaling factor and
water transmission
factor.

(3.11)

PatientScatter Dose
in Water,
DPS,w

Dual Gaussians
multiplied by
empirical, field-size
dependent scaling
factors and water
transmission factor.

(2.28)

Gaussian multiplied
by energy-dependent
scaling factor and
water transmission
factor.

(3.14)
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where AP governs the amplitude of the primary dose on the central axis, C(x, z) and C(y, z)
govern the width and lateral penumbrae of the beam in the x and y directions, x and y are
the lateral distances from central-axis in the plane of calculation for the in- and cross-plane
directions, and T FP,w (x, y, z, E) is the transmission factor of the primary portion of the
beam of nominal energy E at a point (x, y, z) in a phantom.
The C functions in (3.2) model the shape of the primary dose via the simple but
realistic approach of using cumulative normal distributions, as in
1
C(x, z) =
×
2πσ 2 (z)

x

 
−(x0 + x̄(z))2
dx0
exp
2
2(σ
(z))
−∞
P


 
Z x
−(x0 − x̄(z))2
× 1−
exp
dx0
2
2(σP (z))
−∞

Z



. (3.3)

where σP (z) is the width parameter for the cumulative normal functions used to define the
penumbra, and x̄P (z) and ȳP (z) are the centroids of the cumulative normals projected to
depth z. These parameters are described in detail below.
The parameters σP (z), x̄(z), and ȳ(z) are scaled with depth according to

σP (z) = σP,0 × FP (z) ,

(3.4)

x̄(z) = x̄P,0 × FP (z) ,

(3.5)

ȳ(z) = ȳP,0 × FP (z) ,

(3.6)

where σP,0 is the width parameter in the isocentric plane, x̄P,0 and ȳP,0 are the lateral field
edge locations in the isocentric plane. FP (z) is the scaling factor defined as

FP (z) =

SSD + diso + (z − diso ) × αP
SSD + diso

,

(3.7)

where SSD is the source-to-surface distance, diso is the depth at isocenter, and αP is an
empirical correction factor to the rate at which σP (z), x̄P (z), and x̄P (z) change with depth.
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The transmission factor in water at the calculation point is given by

T FP,w (x, y, z, E) = exp [−µP,eff × d(x, y, z)]

,

(3.8)

where the path length through water to point (x, y, z) is

p
d(x, y, z) = (SSD + z)2 + x2 + y 2 ×



z
SSD + z


.

(3.9)

The effective linear photon attenuation coefficient is

µP,eff (E) = (mµ,P × E + bµ,P ) × µ|w,Ē

,

(3.10)

where µP,eff (E) is the effective linear attenuation coefficient in water for the primary portion
of a beam of nominal energy E, and µ|w,Ē is the linear attenuation coefficient in water for
photons of energy Ē, where Ē is the average energy of the photon beam approximated
as one third the value of the nominal energy following Jagetic and Newhauser [26]. The
parameters bµ,P and mµ,P are the 0th and 1st order coefficients, respectively, of an empirical
correction factor to the effective linear attenuation coefficient that is parameterized with
energy. This factor is needed because µ|w,Ē will not equal the true energy weighted mean
of the linear attenuation coefficient, µ(E), across the full energy spectrum of the beam.
The values of the parameters bµ,P and mµ,P are determined along with the other fitting
parameters via the model training procedure described in Section 3.2.3. The values of µ|w,Ē
for the energies considered in this study were found from the National Institute of Standards
and Technology (NIST) XCOM photon cross sections database [27].
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The stray dose is the sum of three terms. The head scatter dose term is the narrowest
laterally and is given by


AHS (E)
−(x2 + y 2 )
√
DHS (x, y, z, E) =
exp
2
2σHS
(z)
σHS (z) 2π

(3.11)

× T FHS,w (x, y, z, E) ,
where AHS (E) is the energy dependent scaling factor given by

AHS (E) = βHS × E + γHS

,

(3.12)

βHS and γHS are the 1st and 0th order coefficients, respectively, that parameterize the factor
with photon beam energy. The depth dependent width parameter, σHS (z), is given by

σHS (z) = σHS,0 × FHS (z) ,

(3.13)

where σHS,0 , is the head scatter width parameter in the isocentric plane, FHS (z) is defined
similarly to (3.7) with empirical adjustment factor αHS , and T FHS,w (x, y, z, E) is the
transmission factor for head scattered radiation defined similarly to (3.8).
The patient scatter dose term is similarly given by


APS (E)
−(x2 + y 2 )
√
DPS (x, y, z, E) =
exp
2
2σPS
(z)
σPS (z) 2π

(3.14)

× T FPS,w (x, y, E) ,
where APS (E) is the energy dependent scaling factor

APS (E) = βPS × E + γPS
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,

(3.15)

βPS and γPS are the 1st and 0th order coefficients, respectively, that parameterize the scaling
factor with photon beam energy, and σPS (z) is a depth dependent width parameter that
scales with depth according to

σPS (z) = σPS,0 × FHS (z) ,

(3.16)

where σPS,0 is the head scatter width parameter in the isocentric plane and FPS (z) is defined
similarly to (3.7) with empirical adjustment factor αPS . The transmission factor for radiation
from patient scatter in a water phantom is given by


p
T FPS,w (x, y, E) = exp −µPS,eff (E) × x2 + y 2 .

(3.17)

The functional form of the leakage dose term is illustrated in Figure 3.1 and is
defined as


AL (E)
−(x2 + y 2 )
√
DL (x, y, z, E) =
exp
2σL2 (z)
σL (z) 2π
× T FL,w (x, y, z, E) × P C(r, z, E)
× [1 − C(x, z) × C(y, z)]

(3.18)

,

where AL (E) is an energy dependent scaling factor

AL (E) = (βL × E + γL ) Fφ

,

(3.19)

and Fφ accounts for increased leakage present in treatments with large amount of photon
fluence modulation. The depth-dependent width parameter from (3.18) is

σL (z) = σL,0 × FL (z) ,
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(3.20)

where FL (z) is defined similarly to (3.7) with a corresponding empirical adjustment factor
αL . The factor [1 − C(x, z) × C(y, z)] suppresses the leakage term inside the treatment field,
and P C(r, z, E) models attenuation in the primary collimator. This primary collimator
function is given by
r


−(r0 + r̄(z))2
P C(r, z, E) = 1 − APC (E) ×
exp
dr0 ,
2
2σPC
−∞
Z

where r =



(3.21)

p
x2 + y 2 , APC (E) is the energy dependent scaling factor

APC (E) = βPC × E + γPC

,

(3.22)

σPC (z) is the width parameter of primary collimator penumbra given by

σPC (z) = σPC,0 × FL (z) ,

(3.23)

and r̄(z) is the lateral location of the primary collimator projected to depth z as in

r̄(z) = r̄0 × FL (z) .

(3.24)

3.2.2. Measurements
There are three distinct sets of measured dosimetric data considered in this manuscript
summarized in Table 3.2. The first set was obtained in this study under the auspices of the
European Radiation Dosimetry (EURADOS) Working Group 9 (WG9), a multinational
collaboration of institutions and researchers dedicated to research and development in the
field of radiation dosimetry in medicine [1]. These experiments were specifically designed to
yield dosimetric data that was needed to understand and model the physics of stray radiation
exposure. The measurement methods and a limited number of preliminary results were
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Figure 3.1. Functional form of the leakage dose, DL , versus off-axis distance, x. In the
in-field region, the leakage dose is defined to be zero. In the intermediate region, leakage is
attenuated by the secondary collimator. Far out of field, there is additional attenuation
from the primary collimator.
previously reported by Bordy et al. [28] The EURADOS data set consists of measurements
made with multiple types thermoluminescent dosimeters (TLDs), radiophotoluminescent
dosimeters (RPLs), and optically stimulated luminescent dosimeters (OSLDs) of doses
delivered by a Saturne 43 linac (GE Medical Systems, USA). The calibration procedure for
the various types of dosimeters is described by Knežević et al. [29]. Doses were measured
at various locations inside a 30 x 30 x 60 cm3 water phantom. This data set includes
dose profiles at 10, 15, 20, and 25 cm depths in water with a source-to-surface distance
(SSD) of 90 cm, a field size of 10 x 10 cm2 , and beam energies of 6, 12, and 20 MV. The
irradiations each delivered a reference dose of 2 Gy to the isocenter located at 10 cm depth.
The measurements from this data set are being prepared for distribution in the form of
electronic files containing complete tables of all numerical data and will be available for
download from the EURADOS website (http://www.eurados.org).
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Table 3.2. Manufacturers, machines, techniques, nominal photon energies, and measurement
phantoms considered in this study. All measurements in the EURADOS and KGU data
sets were taken in water box phantoms. All measurements in the Halg et al. data set were
taken in an anthropomorphic phantom.
Data Set
EURADOS
KGU

MFR.
GE
Elekta
Varian
Elekta

Model
Saturne 43
SL25
Clinac 21 iX
Synergy
Oncor Avant-Garde
(Halg et al.) Siemens
Mevatron Primus
CyberKnife
Accuray
TomoTherapyHi-Art 2

Technique
CRT
CRT
CRT, IMRT
IMRT
IMRT
Wedge
Stereotactic
IMRT

Beam Energy (MV)
6,12, 20
6, 18, 25
6
6
6
6

The second data set used in this work comprises measurements performed at the
Klinikum Goethe Universität (KGU) in Frankfurt, Germany. The KGU data set measurements were made with a diamond detector model (60003 PTW, Freiburg) of doses delivered
by an SL25 linac (Elekta, Stockholm) for various field sizes, depths, and beam energies. For
this work, we consider 10 x 10 cm2 fields at depths of 1.5 and 3.5 cm in water and 100 cm
SSD for beam energies of 6, 18, and 25 MV. These measurements were previously published
in Kaderka et al. [30].
The third data set used in this work comprises doses measured in an anthropomorphic
phantom (Alderson-Rando, RSD Radiology Support Devices, Long Beach, CA) for a variety
of widely used treatment machines and treatment techniques. These measurements were
previously published in Halg et al. [31]. Prostate treatment plans were created for nine
treatment techniques from four manufacturers, including Accuray (Sunnyvale, CA, USA),
Elekta (Stockholm, Sweden), Varian Medical Systems (Palo Alto, CA, USA), and Siemens
(Berlin, Germany). All beams in this data set had a nominal energy of 6 MV. The dose
measurements were performed using TLDs placed inside the anthropomorphic phantom.
The dose along the medial patient axis was determined using 34 TLDs spaced at 2.5 cm
intervals from the target (in prostate) to the head.

47

3.2.3. Model Training
In this work, the analytical model was trained separately using the EURADOS and
KGU data sets. Training was accomplished by simultaneously fitting the parameters listed
in Table 3.5 to measured dose values at all locations and at all beam energies. We used a
gradient search algorithm to vary the free parameters and minimize the sum of the local
relative differences, ∆DTotal , between the predicted and measured values. The sum of total
relative differences was defined according to

∆DTotal =

n
X
i=1

∆Di =

n
X
i=1

"

|Dimodel − Dimeasured |

Dimodel + Dimeasured /2

#
,

(3.25)

where n is the number of data points. In order to characterize the goodness of fit, we
calculated
∆D = ∆DTotal /n ,

(3.26)

where ∆D is the average local relative difference, and

∆Dmax = max ({∆D1 , ..., ∆Dn })

,

(3.27)

where ∆Dmax is the maximum of the local relative differences.
3.2.4. Model Validation
The model, as configured and trained on both the KGU and EURADOS data sets,
was validated by comparison with independent data, namely, the measured dose profiles in
an anthropomorphic phantom for several treatment machines and techniques. Variations in
depth due to the irregular surface contour of the phantom were modeled implicitly since
it has been demonstrated that these variations are modest [24]. We compared the model
as trained on two independent training data sets in order to test the sensitivity of the
agreement to the choice of training data.
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The quality assurance technique known as gamma analysis, first described by Low
et al. [32], characterizes the agreement between measured and calculated dose distributions
on a point by point basis by combining dose difference and distance to agreement criteria.
In most radiotherapy clinics, the dose difference criterion is selected at 3% of the maximum
dose, and the distance to agreement criterion at 3 mm. These values are commonly known
as the Van Dyk criteria [33]. However, this choice is not suitable for application far outside
of the treatment field since dose in this region is well under 3% of the maximum dose,
rendering the test insensitive to important dose errors in the out-of-field region. To overcome
this limitation, we extended the gamma index analysis method that is extended in order to
provide sufficient sensitivity and dynamic range to characterize dosimetric agreement in
both the in-field and out-of-field regions.
The gamma indices at all positions in therapeutic and out-of-field dose regions were
calculated according to

q


 r2 (xm2,xc ) +
∆dT
Γ (xm , xc ) = q


 r2 (x2m ,xc ) +
∆d
OOF

2 (x ,x )
δR
m c
,
2
∆DR

xm in/near field

2 (x ,x )
δA
m c
,
2
∆DA

xm out-of-field

(3.28)

where xm and xc are the locations of measured and calculated dose values, respectively.
r(xm , xc ) is the difference in position between measured and calculated dose values, ∆dT
and ∆dOOF are the distance to agreement criteria in the therapeutic and out-of-field
regions, respectively, δR (xm , xc ) represents the relative dose difference between measured
and calculated dose values, ∆DR is the relative dose difference criterion, δA (xm , xc ) represents
the absolute dose difference between measured and calculated dose values, and ∆DA is the
absolute dose difference criterion. The therapeutic dose region was delineated from the
out-of-field dose region at the 1% relative dose level based on previously published findings
[26, 34–36]. This allows for a significantly more severe dosimetric test out-of-field than
conventional methods. Gamma index analysis was performed separately comparing the
analytical model calculations on each of the two training data sets to the anthropomorphic
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phantom data set for the Varian Clinac 21 iX CRT. Gamma index pass rates were selected
at 100%, 95%, 90%, and 67%. The corresponding gamma index criteria were iteratively
decreased until the analysis yielded the selected pass rate.
3.3. Results
3.3.1. Model Training
Figure 3.2 shows the Elekta SL25 measured and analytical model calculated total
absorbed dose values for the three nominal beam energies (6, 18, and 25 MV) from the KGU
data set. This figure demonstrates excellent agreement between measurement and analytical
model calculations across the range of nominal beam energies considered. Figure 3.3 shows
the measured absorbed dose from the 6 MV beam at a depth 1.5 cm in water plotted with
the analytical model calculated absorbed dose. The individual analytical model dose terms
(i.e. DP , DHS , DPS , DL ) are also plotted thus demonstrating how the combination of these
terms yields excellent agreement in both the in- and out-of-field regions. Table 3.3 shows
the average and local relative differences for the model compared with the KGU dataset
including the 6 MV beam at a depth of 1.5 cm and the 18 and 25 MV beams each at a
depth of 3.5 cm. The average local relative difference, defined in (3.26), was 9.9%. The
maximum local relative difference, defined in (3.27), was 33%.
Table 3.3. Average and maximum local relative differences for all nominal photon beam
energies E for the model calculations compared with the Klinikum Goethe Universität
(KGU) data set.
E
6 MV
18 MV
25 MV
All Energies

∆D(%)
7.1
12.3
8.1
9.9

∆Dmax (%)
23.9
32.9
33.0
33.0

Figure 3.4 shows plots of Saturne 43 measured and analytical model calculated
absorbed dose for the 6, 12, and 20 MV nominal beam energies at depths in water of 10
and 25 cm from the model as trained with the EURADOS data set. Very good agreement
is seen between the model and the training data, showcasing the ability of the model to
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Figure 3.2. Measured and calculated relative absorbed dose D(x)/D(0) versus off-axis
position x for all beam energies from the Klinikum Goethe Universität (KGU) data set.
The abscissa corresponds to the lateral distance from the central axis of the beam. The
ordinate represents the relative absorbed dose as a function of x. All profiles are at dmax
(1.5 cm for 6 MV and 3.5 cm for 18 and 25 MV) and were normalized to the value of dose
at x = 0. For visual clarity, the profiles are offset by factors of 10.
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Figure 3.3. Measured and calculated relative absorbed dose D(x)/D(0) versus off-axis
position x from the 6 MV beam at 1.5 cm depth in water from the Klinikum Goethe
Universität (KGU) data set.
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accurately calculate absorbed dose across a range of energies and depths. Figure 3.5 show
the measured absorbed dose from the 6 MV beam at a depth 10 cm in water plotted with
the analytical model calculated absorbed dose and all individual dose components. Table
3.4 lists the average and maximum local relative differences for all energies and depths
included in this data set. The average difference for all locations and energies considered
was 9.9% and the maximum difference was 41%.

I  Field

Out-of-Field
6 MV, d = 10 cm
6 MV, d = 25 cm
12 MV, d = 10 cm
12 MV, d = 25 cm
20 MV, d = 10 cm
20 MV, d = 25 cm
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Figure 3.4. Measured and calculated relative absorbed dose D(x)/Diso versus off-axis
position x for 6, 12, and 20 MV beams at 10 cm and 25 cm depths in water from the
European Radiation Dosimetry Group (EURADOS) data set. The abscissa corresponds
to distance from the central axis of the beam. The ordinate corresponds to the relative
absorbed dose as a function of x. The profiles were normalized to the value of dose at
isocenter for the given beam energy. For visual clarity, the profiles were offset from one
another by factors of 10.
The model parameter values resulting from fitting the model to the KGU and
EURADOS data sets of measurements in water are listed in Table 3.5. The relative
differences between the parameters as fit on these data sets are also listed. The primary
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Figure 3.5. Measured and calculated relative absorbed dose D(x)/D(0) versus off-axis
position x for the 6 MV beam at 10 cm depth in water from the European Radiation
Dosimetry Group (EURADOS) data set.

Table 3.4. Average and maximum local relative differences for all nominal photon beam
energies and depths for the model calculations compared with the European Radiation
Dosimetry Group (EURADOS) data set.
Depth
6 MV
(cm) ∆D(%) ∆Dmax (%)
10
10.2
26.9
15
11.8
31.2
20
9.8
41
25
8.6
30.3
All
10.1
41
Depth
20 MV
(cm) ∆D(%) ∆Dmax (%)
10
11.8
30.7
15
10.6
34.6
20
9.1
31.7
25
10.8
27.4
All
10.6
34.6
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12 MV
∆D(%) ∆Dmax (%)
10.3
25.2
9.5
27.9
7.4
20.3
8.8
26.5
9
27.9
All Energies
∆D(%) ∆Dmax (%)
10.8
30.7
10.6
34.6
8.7
41
9.4
30.3
9.9
41

dose parameters resulting from fitting the model to each of the two data sets are similar
with no parameter differing by more than 33.5%. However, there are considerable differences
between the parameters for the out-of-field dose components, thus highlighting the ability
of the model to adapt to out-of-field dose profiles of different machines.
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Table 3.5. Model parameters for model as trained on Klinikum Goethe Universität (KGU) and European Radiation Dosimetry
Group (EURADOS) data sets and the relative differences between the results for each.
Term

Description
Symbol
KGU
Dose coefficient
AP (mGy/Gy)
982
Field edge
x̄P,0 (cm)
5.0
Penumbra
σP,0 (cm)
0.33
Primary
Projection correction factor
αP (—)
1.1
th
Attenuation 0 order coefficient bµ,P (—)
1.0
Attneuation 1st order coefficient mµ,P (MeV-1 )
5.2×10-2
Dose 0th order coefficient
βHS (mGy/Gy)
9927
st
Dose 1 order coefficient
γHS (mGy/Gy/MeV)
722
Head
Width parameter
αHS,0 (cm)
4.2
Scatter Projection correction factor
αHS (—)
0.88
Attenuation 0th order coefficient bµ,HS (—)
3.0×10-3
Attneuation 1st order coefficient mµ,HS (MeV-1 )
3.5×10-2
Dose 0th order coefficient
βPS (mGy/Gy)
7717
Dose 1st order coefficient
γPS (mGy/Gy/MeV)
-145
Patient Width parameter
αPS,0 (cm)
15.0
Scatter Projection correction factor
αPS (—)
0.60
Attenuation 0th order coefficient bµ,PS (—)
0.88
st
-1
Attneuation 1 order coefficient mµ,PS (MeV )
-1.8×10-2
th
Dose 0 order coefficient
βL (mGy/Gy)
9601
Dose 1st order coefficient
γL (mGy/Gy/MeV)
-100
Width parameter
αL,0 (cm)
340
Projection correction factor
αL (—)
0.80
Attenuation 0th order coefficient bµ,L (—)
1.7
Leakage
st
-1
Attneuation 1 order coefficient mµ,L (MeV )
-4.7×10-2
th
PC 0 order coefficient
βPC (—)
0.46
st
-1
PC 1 order coefficient
γPC (MeV )
4.0×10-3
PC location
x̄PC (cm)
25.0
PC penumbra
σPC,0 (cm)
5.0×10-3
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EURADOS
1326
4.9
0.33
0.78
1.1
5.7×10-2
16195
263
4.1
0.79
8.3×10-3
5.0×10-2
9616
-342
12.0
0.58
0.49
-1.5×10-2
13287
-613
239
0.80
0.90
-5.0×10-2
0.35
3.5×10-3
24.0
5.0×10-3

Rel. Diff.
29.9%
1.4%
1.6%
33.5%
12.1%
8.5%
48.0%
93.3%
4.0%
10.8%
94.9%
35.6%
21.9%
80.9%
21.9%
3.6%
56.4%
13.7%
32.2%
143.9%
34.8%
0.7%
63.9%
6.6%
28.3%
11.4%
4.3%
0.0%

3.3.2. Validation with anthropomorphic phantom measurements
Doses measured in an anthropomorphic phantom for all nine treatment machines
considered are shown in Figure 3.6. Also shown on this plot are the calculated doses from
the analytical model as trained on both the KGU and EURADOS data sets from the
previous section. The gamma index criteria required to achieve the selected passing rates
are listed in Table 3.6.
In/Near Field

Out-of-Field
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Figure 3.6. Relative absorbed dose D(x)/D(0) versus off-axis position x in anthropomorphic
phantom from irradiations by various treatment techniques and machines. Points represent
measured doses. Lines represent analytical model calculations from the model as trained
on the Klinikum Goethe Universität (KGU) and European Radiation Dosimetry Group
(EURADOS) data sets, respectively.

The large differences in leakage radiation seen in the measured profiles in Figure
3.6 are due to differences in the fluence modulation used for the different techniques, as
well as variations in collimators and head shielding in various machines. For example, the
increased leakage from the CyberKnife unit was likely due to reduced head shielding in
order to facilitate the mounting of the linac on a robotic arm. On the other hand, the
increased leakage from the wedged field technique was due to the greater beam-on time
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Table 3.6. Gamma index criteria for selected pass rates when comparing the model as
trained on the Klinikum Goethe Universität (KGU) and European Radiation Dosimetry
Group (EURADOS) data sets to the anthropomorphic phantom data set for the Varian
Clinac 21 iX. The criteria considered include relative dose difference, ∆DR ; absolute dose
difference, ∆DA ; and distance to agreement in the therapeutic and out-of-field regions, ∆dt
and ∆dOOF , respectively.
Therapeutic

Out-of-Field
∆DA ∆d
OOF
mGy
Gy
(mm)
3.5
0.5
3.1
0.5
2.2
0.5
0.3
0.5

Training
Data Set

Pass
Rate

∆DR
(%)

∆dt
(mm)

KGU

100
95
90
67

8
6
4
3

18
14
10
7

100

15

20

4.5

0.5

95
90
67

11
8
6

16
12
8

3.9
2.5
0.6

0.5
0.5
0.5

EURADOS

required to produce wedged fields. Dose profiles from special techniques such as these should
not be expected to closely match the dose profiles of more typical treatment techniques,
e.g., IMRT. By fitting the model parameters for each curve individually, it is possible to
faithfully reproduce each of the measured dose profiles in a descriptive capacity (not shown),
but additional development is necessary to extend the model to include explicit modeling of
fluence modulation for predictive purposes.
3.4. Discussion
This work strongly suggests that there is potential for improving the completeness
and accuracy of dose distribution calculations in routine clinical applications. The model
is not intended to replace current methods of treatment planning, but could be used in
conjunction with current methods to provide a level of accuracy for the dose far outside the
treatment field that is not available from currently available commercial treatment planning
systems. With further study, this model could be implemented for use in hand calculations
of fetal dose in the case of a pregnant radiation therapy patient or the dose to implants
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such pacemakers that may be damaged by radiation. Additionally, the ability to calculate
therapeutic and stray radiation with a single model should be useful for studies in radiation
epidemiology or as an educational tool for demonstrating the shape and relative magnitudes
of the dose distributions from various treatment machines and techniques. Importantly, this
may all be possible with a single analytical model that users may implement with measured
data that is likely to already exist for their clinic.
The results of this study are consistent with previous works related to analytical
models of total dose from external beam radiation therapy. In particular, the results achieved
in this work agree well with those of a more complex model previously reported by Jagetic
and Newhauser [26]. The model offers simplicity, easy portability to various treatment
machines and techniques, and increased speed compared with the more detailed model of
Jagetic and Newhauser.
Major strengths of this study include the large number of treatment machines and
techniques considered. Whereas previous works have been limited to single treatment
techniques, this work considers nine techniques delivered with seven treatment machines
from four manufacturers. This is made possible by the simplicity of the reported model.
Additionally, in demonstrating the accuracies that are achievable with such a simple model,
this work informs about the tradeoff between accuracy and complexity for analytical dose
models.
Limitations of this work include the limited amount of measured data taken for each
treatment technique. Additionally, only the descriptive capabilities of the model have been
examined in this work, and the model’s ability to predict doses for treatments with different
setup conditions has not been tested. This is not a serious limitation because a lookup
table approach could be used to apply this model to many different setup conditions with
only a few measurements required. Another limitation of the model, in its current form,
is the lack of photoneutrons at beam energies greater than 10 MV. However, this is not
a serious limitation because most external beam photon treatments are delivered with 6
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MV beams. This is especially true of IMRT. Additionally, for beam energies up to 18 MV,
the component of equivalent dose due to photoneutrons is a small fraction of that due to
leakage photons [30]. Also, the model can be extended to include photoneutrons in future
studies. Other future work should include testing the model for dosimetric accuracy under
different treatment conditions, such as field size. Additionally, implementing the model into
a treatment planning system would allow for further testing of the practicality of using
analytical models of stray dose in clinical settings. Our research group has recently performed
similar work by implementing an analytical model of neutron dose from passively-scattered
proton therapy into a research treatment planning system [37].
3.5. Conclusion
In this work we developed a new, broadly-applicable analytical model of the total
dose from external beam radiation therapy. The model provides very good accuracy, on
average better than 10%, for both therapeutic and stray dose for a wide variety of treatment
machines and techniques when compared with measured data. Importantly, the model
developed here may be configured using non-proprietary configuration parameters and
dosimetric data that is readily measurable in most clinics.
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Chapter 4.
A Physics-Based Analytical Model of Absorbed Dose from Primary, Leakage, and Scattered Photons from Megavoltage Radiotherapy with MLCs
4.1. Introduction
The goal of modern radiation therapy is to eradicate or control diseased tissues
and to spare healthy tissues to the greatest extent possible. The side effects of radiation
exposure to healthy tissue range from mild to severe and can be categorized as either
acute or late-occurring. Late-occurring side effects of radiation include ailments such as
cardiac toxicity and radiation induced second cancers [1–4]. These effects can occur up to
decades after treatment, including in tissues far from the location of the primary tumor [5].
In particular, most radiation induced second cancers occur outside of the treatment field
boundaries [6]. It logically follows that radiation exposures from both therapeutic and stray
radiation should be known in order to project treatment efficacy and radiation side effects.
Radiation therapy, along with surgery and chemotherapy, is one of the central
treatment options available to cancer patients. Approximately one-half to two-thirds of
cancer patients in developed nations receive radiation therapy at some point during their
care [7]. Recent studies have confirmed that improvements in survival rates have led to an
increasingly large population of cancer survivors and, therefore, an increasing prevalence of
patients suffering from late-effects of radiation therapy [8–10]. This has caused mounting
interest in research into accurately characterizing the dose to a patient’s whole body [4, 11,
12].
In external beam radiation therapy, the sparing of healthy tissue is achieved through
the use of collimators to tightly conform the boundaries of the radiation field to shape of the
planning target volume (PTV). However, lower levels of stray radiation, including scattered
and leakage radiation, still reach a patient’s healthy tissues. Remarkably, contemporary
clinical treatment planning systems accurately calculate the in-field dose but systematically
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underestimate the absorbed dose outside of the PTV by 40–100% in some cases [13–18]. In
the literature, far more attention has been paid to exposures in and immediately near the
treatment field because their importance in controlling malignant disease [4, 19].
Attempts to characterize the stray radiation exposures from photon radiotherapy
delivered with electron linacs have made use of measurements [20–22], Monte Carlo simulations [23–27], and empirical parameterizations [28–30]. Sánchez-Nieto et al. [31] reported an
analytical model for calculating stray-dose from photon beams applicable along the midline
of a patient in the isocentric plane at distances ≥ 10 cm from the field edge. A recent work
from Hauri et al. [32] modeled patient-scattered radiation as a disk source and relied on
machine specific parameterizations of head-scattered and leakage radiation. Previously,
we demonstrated the feasibility of physics-based analytical models for calculating total
body dose for 6-MV CRT [17]. Subsequently, we showed that such methods are broadly
applicable to a wide variety of treatment machines and techniques [33]. However, these
models were developed and validated only for the in- and cross-plane axes and approximated
collimators as semi-infinite planes. Furthermore, the individual components of the stray
dose model (leakage, head-scatter, and patient-scatter) were not verified by comparison
with measurements or Monte Carlo simulations.
The objective of this work is to develop a new physics-based, analytical model of
therapeutic and stray radiation that can calculate attenuation through clinically realistic
collimator geometries including multileaf collimators (MLCs). Additionally, we aim to
verify the dosimetric accuracy of all radiation components at all locations. We measured
absorbed dose distributions from 6-MV beams incident on a water-box phantom to obtain
data for configuring the model. We performed Monte Carlo simulations to independently
determine the photon energy-fluence and dose from primary, leakage, and scattered photons.
This allowed us to separately model the contributions to dose from each component and to
realistically model the influence of the rounded and flat edges of the collimators.
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4.2. Methods and Materials
4.2.1. Definitions
In the literature, the terminology and nomenclature used for the sources of stray
radiation incident on a patient are myriad, ambiguous, and often inconsistent [12]. In
this work, uncollided radiation refers to those photons generated in the tungsten target
that have not interacted in any other object. Those uncollided photons that pass through
the treatment aperture comprise the primary radiation field. The uncollided photons that
travel through one or more beam-limiting devices without interacting are considered leakage
radiation. Photons that undergo scattering events in the linac head are labeled head-scatter.
Finally, patient-scattered radiation comprises photons that undergo scattering events within
the patient or phantom.
4.2.2. Measurements
We took measurements of absorbed dose to serve as validation data for the analytical
model described in Section 4.2.4. Measurements were taken with two active dosimeter
types. The primary detector used was a Farmer-type ionization chamber (TM 30013, SN
009214, PTW, Freiburg, Germany). This is a waterproof chamber regularly used for both
absolute and relative photon dosimetry. It has a sensitive volume of 0.6 cm3 and a flat
energy response from 30 kV to 50 MV photon-beam energy [34]. To ensure adequate spatial
resolution in high-dose-gradient regions, we also measured with a waterproof solid-state
diode dosimeter (TM 60012, SN 00579, PTW, Freiburg, Germany). The diode detector
has a water-equivalent window thickness of 1.33 mm and a 1 mm2 by 30 µm thick circular
sensitive volume. Measurements from both detectors were corrected for variations in photon
spectral fluence following the methods of Chofor et al. [35, 36].
All measurements were performed at the Metrological ELectron Accelerator Facility
(MELAF) at the Physikalisch-Technische Bundesanstalt (PTB) in Braunschweig, Germany
[37]. The facility has two linacs (Precise Treatment SystemTM , SN 151605 and 151617,
Elekta, Stockholm, Sweden) dedicated to metrology and research. The first of the linacs was
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commissioned to deliver 6-, 10-, and 15-MV photon beams, and the other was commissioned
for 4-, 8-, and 25-MV photon beams. The gantry angle was set to 270◦ for all measurements.
Dose rates were controlled through the use of a high-precision transmission monitor system
[38].
Measurements were conducted in air and in a water-box phantom. In both cases,
detector positioning was accomplished using the PTB in-house scanning system. For the
in-water measurements, a 60×60×60 cm3 phantom with 1-cm thick plastic (polymethyl
methacrylate or PMMA) walls with a water-equivalent thickness of 1.1 cm. The phantom
was filled with distilled water and carefully positioned to achieve a source-to-surface distance
(SSD) of 90 cm, placing isocenter at an axial distance of 10 cm distal to the upstream face
of the phantom wall upon which the beam impinged. The phantom was positioned laterally
such that isocenter was 11 cm from both the bottom and nearest lateral side faces of the
phantom. This asymmetric positioning allowed for half-profile scans extending to an off-axis
distance of 40 cm in both the x- and y-direction and depths of up to 40 cm while always
maintaining at least 9 cm between the detector and phantom edge. Due to the finite detector
size and 1.1 cm water-equivalent thickness of the phantom wall, the shallowest depth at
which measurements were achievable was 2 cm. In order to ensure adequate side-scatter, a
smaller 30 ×30 ×30 cm3 water phantom, also with 1-cm thick plastic walls was abutted
directly against the large phantom. A photograph of the measurement setup is displayed in
Figure 4.1.
4.2.3. Monte Carlo Simulations
Monte Carlo simulations of absorbed dose were performed to serve as training data
for the analytical model described in Section 4.2.4. We simulated the linac, water-box
phantom, and vault of the PTB facility. Monte Carlo simulations of photon fluence and
total absorbed dose were performed using the Monte Carlo N-Particle eXtended (MCNPX)
transport code version 2.7 [39]. The model of the linac in use at PTB was designed based
on schematics provided by the manufacturer [40]. We modeled all major beam modifying
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Figure 4.1. Photograph of measurement setup. The gantry is rotated to 270° with the
upstream face of the phantom walls located at 90 cm SSD. The large phantom (A) is
positioned in from of the linac aperture. The small phantom (B) is behind the large
phantom in this photo. The arm used to scan the detectors is also visible (C).

Table 4.1. Measurement conditions for all absorbed dose profiles scanned in of this work.
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Figure 4.2. (a) Cross-sectional schematic view of linac head illustrating the relative locations
of the beam-modifying and beam-limiting devices including the X-ray target, the cylindrical
primary collimator, the flattening filter, the monitor chamber, the multi-leaf collimators
(MLCs), and the jaws (not to scale). The location of the MLCs is rendered with a dotted
line since the MLC leaves may not extend into the xz-plane for a given field. (b) Plan view
of the vault geometry of the PTB metrology facility including A, the vault; B, linac head
and phantoms; C, primary barriers; D, secondary barriers; E, inner-maze wall; F, maze;
and G, door.
devices including the high-Z x-ray target, flattening filter, and monitor ionization chambers.
The beam limiting devices modeled include the conical primary collimator, the multileaf
collimator with backup diaphragm, and the jaws. Figure 4.2a illustrates the components
of the linac treatment head. The gantry angle of the simulation matched the 270° angle
employed for the physical measurements. The simulated field sizes included 2×2, 5×5,
10×10, 14×14, and 20×20 cm2 .
The geometry, density, and material composition of the treatment vault were taken
from as-built drawings and other design documents. The main area of the treatment vault
is approximately 10×9 m2 with a ceiling height of 5 m. The floor, ceiling, and all secondary
barriers, including the maze walls, are shielded with standard concrete of density 2.38 g/cm3 .
The sections of the walls designated as primary barriers were shielded with heavy concrete
of density 3.28 g/cm3 . A plot of the treatment vault geometry is shown in Figure 4.2b. The
60×60×60-cm3 and 30×30×30-cm3 phantoms were positioned in the simulation exactly as
they were for the measurements. Each phantom had 1-cm thick PMMA walls on the sides
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and bottom. The water inside the large phantom was broken into 1-cm3 cubic voxels. The
water-box phantoms in use at PTB were also modeled. Both photons and electrons were
transported, and the total absorbed dose to each voxel was found by taking the sum of
F6-type energy deposition lattice tallies for both particle types.
We used an F4-type lattice tally to determine the photon fluence in each voxel. In
order to obtain the photon spectral fluence, we binned the fluence tally logarithmically
between 1 eV and the maximum energy of electrons impinging on the target. To separate
the total photon spectral fluence into the spectral fluence from uncollided, head-scattered,
and patient-scattered photons, we used the TAG card to bin the F4 tally by the cell in which
the photons were created. Photons created in the target or backing plate were summed to
yield the uncollided photon spectral fluence. Photons created in the phantoms, including
the water and the plastic walls, were summed to yield the patient-scattered spectral fluence.
Photons created in other cells were binned and summed to yield the head-scattered spectral
fluence. For each of these components, we found the photon energy fluence by multiplying
each bin by its corresponding midpoint energy and summing over all energy bins. We found
the mean photon energy of each component by dividing the photon energy fluence by the
photon fluence.
Since the analytical absorbed-dose model described in Section 4.2.4 requires the
mean photon energy at the point of calculation, we developed simple parameterizations
of mean energy with location in the phantom for each of the three components described
above, or
E n (x, y, z) = E n,cax (z) × (1 − An (z) × CDFn (x, y, z))

,

(4.1)

where n = 1 for uncollided photons, n = 2 for head-scattered photons, and n = 3 for
patient-scattered photons. The mean energy along the beam’s central axis is modeled as

E n,cax (z) = aE,n × z + bE,n
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,

(4.2)

where aE,n and bE,n are empirical fitting parameters. The cumulative normal function
CDFn (x, y, z) governs the shape of the mean energy curve off-axis and is defined as
"
1
CDFn (x, y, z) =
1 + erf
2

!#
p
FS×z
x2 + y 2 − fn × 2×z
iso
√
FS×z
2 × σ0,n × 2×z
iso

,

(4.3)

where erf is the error function, FS is the side-length of the equivalent square of the field,
and fn and σ0,n are empirical fitting parameters. Finally, An (z) governs the magnitude of
the change in mean energy from central-axis to points far off-axis and is given by

An (z) = cE,n × z 2 + dE,n × z + eE,n

,

(4.4)

where cE,n , dE,n and eE,n are empirical fitting parameters.
4.2.4. Analytical Model
4.2.4.1. Model Components
The model of absorbed dose comprises the sum of three terms, or

DT (x, y, z) = DP (x, y, z) + DL (x, y, z) + DHS (x, y, z) + DPS (x, y, z) ,

(4.5)

where DP (x, y, z) is the dose from primary photons, DL (x, y, z) is the dose from leakage
photons, and DHS (x, y, z) and DPS (x, y, z) are the doses from head- and patient-scattered
photons, respectively. The axes of the coordinates x and z are shown in Figure 4.2a with
the y-axis extending out of the page and the origin located at the target. The four terms of
the absorbed dose model are, in turn, based on models of photon energy fluence, Ψ . The
total photon energy fluence is modeled as

Ψ (x, y, z) = ΨP (x, y, z) + ΨL (x, y, z) + ΨHS (x, y, z) + ΨPS (x, y, z) ,
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(4.6)

where ΨP (x, y, z) + ΨL (x, y, z) represents the energy fluence from primary and leakage
photons, ΨHS (x, y, z) from head-scattered photons, and ΨPS (x, y, z) from patient-scattered
photons. These terms will be described in Section 4.2.4.4 and Sections 4.2.5 and 4.2.6.
4.2.4.2. Photon Source Model
Before describing the terms in Equation 4.6, we must describe the model of the
photon source. The approach follows that of Jagetic and Newhauser [17], but with several
important changes. While previous models have been based on modeling photon fluence and
converting this to absorbed dose by assuming an average energy value, our model directly
and explicitly models photon energy fluence, Ψ (x, y, z).
In a medical linac, the primary photon fluence is produced by impinging a narrow
beam of megavoltage electrons onto a tungsten target, thus generating bremsstrahlung
photons. This bremsstrahlung radiation is sharply forward peaked. Often, a laterally-flat
absorbed dose distribution is desired at the depth of the tumor, and so the flattening filter
is designed to preferentially attenuate photons on and near the beam’s central-axis. This
results in a distribution that is flat at a depth of 10 cm in water, but which exhibits off-axis
peaks, referred to as horns, at shallower depths. For this reason, the uncollimated photon
energy fluence is modeled as the sum of three terms, or

ΨUC (x, y, z) =

3
X

Ψi (x, y, z) .

(4.7)

i=1

The first term, Ψ1 (x, y, z), models the bulk of the flattened beam and is centered on the
beam’s central axis. The energy-weighted sum of the number of photons in each peak is
calculated as
Si = Y (T0 ) × T0 ×
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Qi
e

,

(4.8)

where Qi is the total charge of electrons contributing to the ith source term, e is the
elementary charge, T0 is the nominal energy of the electron beam (i.e., 6 MeV), and Y (T0 )
is the the thick target photon radiation yield for electrons of energy T0 . This is a unitless
quantity with value 0.2157 [41].
The first source term, denoted by G1 (x, y, z), corresponds to the flat central region
with Gaussian-like lateral fall-off and is modeled through the use of a cumulative normal
function, or
)

 2
−ρ (x, y)
S1
√ × 1 − αG1 ×
dρ(x, y)
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exp
2
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−∞
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 2
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1 1
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+ erf
2 2
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(

Z
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(4.9)

where S1 is as defined in Equation 4.8, αG1 is an empirical fitting parameter, ρ(x, y) is the
distance from the beam’s central axis to the point of interest at (x, y) in the calculation
plane, and σ1,z (z) is the width parameter projected to the calculation plane at distance z.
The second and third source terms are
"
2 #
− ρ2 (x, y) − ρi,z (z)
Si
√ exp
Gi (x, y, z) =
, for i = 2, 3 ,
2
2σi,z
(z)
σi,z (z) 2π

(4.10)

where Si is as defined in Equation 4.8, σi,z (z) is the width parameter of the ith Gaussian,
ρ(x, y) is the lateral distance of the calculation point from the central axis , and ρi,z (x, y, z) is
the centroid of the ith Gaussian projected to the plane of the point of calculation at distance
z. The Gaussian width parameters and centroid positions scale with depth according to
geometric magnification, or
z + d0
z
z + d0
×
z

σi,z (x, y, z) = σi,0 ×

,

(4.11)

ρi,z (x, y, z) = ρi,0

,

(4.12)
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where σi,0 , ρi,0 , and d0 are empirically determined fitting parameters of the model with d0
representing the location of the photon virtual source (see Figure 4.3).
Using the terms described in Equations 4.9 and 4.10, the uncollimated photon energy
fluence from the ith Gaussian source, Ψi (x, y, z), is defined as

Ψi (x, y, z) =

Gi (x, y, z)
, for i = 1, 2, 3 ,
4π [ri (x, y, z)]p

(4.13)

where p is an exponent that governs the divergence and ri (x, y, z) represents the distance
from the centroid of the ith Gaussian in the source plane to the point of interest calculated
according to
ri (x, y, z) =

q
ρi (x, y)2 + z 2

,

(4.14)

where ρi (x, y) is defined as

ρi (x, y) =

p

x2 + y 2 − ρi,0

.

(4.15)

4.2.4.3. Model of Primary Collimator Attenuation
Section 4.2.4.2 described the model of the photon source energy fluence in-air. To
determine the photon energy fluence incident on the patient, we must to model photon
attenuation through the various beam limiting devices (BLDs) to obtain the collimated
photon energy fluence. As shown in Figure 4.2, the BLD nearest to the target is the primary
collimator, which has the form of a cylinder made of tungsten alloy with an aperture in
the center in the shape of a conical frustum. Figure 4.3 shows a cutaway drawing of the
primary collimator including the dimensions used by the model.
In order to model the collimation of the photon energy fluence at a given point of
calculation, (x, y, z), we must find the thickness of the primary collimator as seen by a ray
from each of the three source locations to the calculation point. We define the ray angle, θ,
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Figure 4.3. Cutaway illustration showing a 3D drawing of half of the primary collimator.
ρPC,0 is the radius of the aperture at the bottom face of the primary collimator. tpc is
the vertical thickness of the primary collimator. rPC (x, y, z) is the length of a ray passing
through the primary collimator used in determining the attenuation.
from the ith source to the calculation point as

θi (x, y, z) = tan

−1



ρi (x, y)
z


,

(4.16)

where ρi (x, y) is as defined in Equation 4.15. As illustrated in Figure 4.3, the distance that
a ray emanating from the ith source travels through the primary collimator is

ri,PC (x, y, z) =

zi,PC (x, y, z)
cos[θ(x, y, z)]

,

(4.17)

where zi,PC (x, y, z) is the projection of ri,PC (x, y, z) onto the z-axis and is calculated as



0,
for
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<

ρi,PC(x,y)
zPC,t

. (4.18)

The transmission factor of the primary-collimator is calculated from ri,PC (x, y, z) as




TFi,PC (x, y, z) = exp −αµ,PC,i × µC E 1 (x, y, z) × ri,PC (x, y, z)

,

(4.19)


where µC E 1 (x, y, z) is the linear attenuation coefficient of the collimator material found
using the methods of Sutcliffe [42] for photons of energy E 1 (x, y, z), and αµ,PC,i is an
empirical adjustment factor to the primary collimator attenuation for the ith source.
4.2.4.4. Model of Secondary Collimator Attenuation
After the primary collimator, the field passes through two sets of secondary collimators. The jaws and MLC leaves are flat on all sides except for the inward faces of the MLC
leaves that define the edge of the field, which are circular arcs. Boyer and Li [43] previously
reported an analytical formula for determining the special case of the distance a ray from the
photon source to the isocentric plane must travel through a rounded collimator edge. Here,
we present a general solution for rays extending to any z. Figure 4.4 shows a cross-section
of the shape used to model the secondary collimators with the relevant dimensions labeled.
For a ray tangent to the circular face of the collimator emanating from ith Gaussian
source, xtan and ztan are the distances to the tangent point from the x− and z−axes as
shown in Figure 4.4. Since these distances are not known a priori, we calculate their ratio
according to

xtan
=
ztan

zj × (−xj,k − Rj ) + Rj

q

zj2 + (xj,k + Rj )2 − Rj2

Rj2 − zj2

.

(4.20)

Rays with θx < tan−1 (xtan /ztan ) do not intersect the collimator. For those rays that
do intersect the collimator, the distance traveled through the collimator depends upon
the surfaces through which the ray enters and exits, as illustrated in two dimensions in
Figure 4.5. For simplicity, let us first consider the case of rays limited to the in- and
cross-planes. In order to determine the path length a given ray takes through the collimator,
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Target

x

θtan

zj,t
Rj

xj,k

o

zj

ztan
xtan
zj,b
lj

z

Figure 4.4. Schematic cross-sectional view of an MLC leaf. The index j is 2 if the collimator
is an an MLC. The length of the collimator is denoted lj . The point o marks the origin
of the circular arc that defines the collimator edge, and Rj is the arc’s radius. zj is the
z-distance from the photon source to the point, o, with zj,t and zj,b labeling the upstream
and downstream faces of the collimator, respectively. thetatan is the angle that a tangent
ray from the source to the circular collimator face makes with the z-axis, with xtan and ztan
being the coordinates of the tangent point. The distance from the photon-beam central-axis
to the tip of the collimator is xj,k where k denotes whether this is a positive or negative
side collimator. Note: Drawing not to scale.
we must determine the z−values at which it enters and exits the collimator. The z−values
of the top and bottom of the collimators are known. For rays that pass through the circular
face of the collimator (surface F in Figure 4.5), the z−values at which the ray intersects the
imaginary circle that defines the curvature can be calculated as the solutions to a quadratic
equation, or


q
2
z Rj x + xxj,k + zzj − Rj2 x2 − (xj,k z − xzj ) + 2Rj z (xzj − xj,k z)
zj,k,t,F (x, z) =

x2 + y 2
(4.21)

and
q

2
2 2
z Rj x + xxj,k + zzj + Rj x − (xj,k z − xzj ) + 2Rj z (xzj − xj,k z)


zj,k,b,F (x, z) =

x2 + y 2

,

(4.22)
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where zj,k,t,F and zj,k,b,F are the z-locations at which the ray enters and exits the rounded
collimator face, respectively.
Next, we determine the two z-values of interest for any ray traveling in in-plane or
cross-plane (i.e., in the x − z- or y − z-planes). The z-value at which the ray enters the
collimator is



for xz



N/A



or xz













for xz
zj,k,t,c (x, z) =
zj,k,t,F (x, z) ,


and zj,k,t,F (x, z)













for zj,k,t,F (x, z)
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and x
z
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≤

xtan
ztan

>

xj,k +lj
zjt

>

xtan
ztan

≥ zjt

< zjt
≤

xj,k +lj
zjt

,

(4.23)

where zj,k,t,F (x, z) is as defined in Equation 4.21 and the z-value at which the ray exits the
collimator is

zj,k,b,c (x, z) =




for xz



N/A



or xz














for xz



zj,k,b,F (x, z) ,



and zj,k,b,F (x, z)












zjb ,


















y2jr z


,

 y

≤

xtan
ztan

>

xj,k +lj
zjt

>

xtan
ztan

≤ zjb
,

(4.24)

for zj,k,b,F (x, z) > zjt
and

x
z

≤

xj,k +lj
zjb

for

x
z

>

xj,k +lj
zjb

and

x
z

≤

xj,k +lj
zjt

where zj,k,b,F (x, z) is as defined in Equation 4.22. In Equations 4.23 and 4.24, N/A indicates
that a ray does not intersect the collimator.
The preceding formulas are sufficient for rays limited to in- and cross-planes, but in
order to describe other rays we must consider the 3-dimensional case. Figure 4.6 illustrates
the additional types of rays to consider when modeling the horizontal extent, including frontside (FS), top-side (TS), front-rear (FR), side-bottom (SB), side-rear (SR), and side-side
(SS).
Once the z−values of entry and exit have been determined (Equations 4.23 and 4.24),
the total distance traveled through the collimator is subsequently calculated as

rj,k (x, y, z) =

zj,k,b (x, y, z) − zj,k,t (x, y, z)
cos[θ(x, y, z)]
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.

(4.25)

Target

x

T

F

N/I

R

B
N/I

FF

FB

TB

TR

z
Figure 4.5. 2-dimensional drawing of an MLC leaf illustrating the types of rays that must be
considered. Surfaces are labeled F (front), T (top), B (bottom), and R (rear). Rays marked
N/I (non-intersecting) are those rays that do not pass through the collimator material. The
other rays are labeled according to the surfaces through which they enter and exit the
collimator: FF (front-front), FB (front-bottom), TB (top-bottom), and TR (top-rear).

TS
FS

FF

FB

TB

TR

SB

FR

Figure 4.6. 3-dimensional schematic drawing of secondary collimator leaves, illustrating
the effect of considering the horizontal extent. The labels F, B, T, and R correspond to
those in Figure 4.5 with the addition of S (side). The four central rays, FF through TR, are
similar to the four intersecting rays illustrated in Figure 4.5. However, the two leftmost rays
illustrate that it also possible for a ray to enter through either the front or the top of the
collimator and leave through surface S (side). The offset section of collimator on the right
demonstrates the additional types of rays to consider for offset MLC leaves where rays may
enter through the side and exit through the bottom (B), rear (R), or the other side (S).
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The transmission factor of the ray through the collimator is




TFj,k (x, y, z) = exp −αµ,j,k × µC E 1 (x, y, z) × rj,k (x, y, z)

,

(4.26)

where αµ,j,k is an empirical adjustment factor to the attenuation coefficient of the collimator.
The final step before converting photon energy fluence to dose was to calculate
the attenuation due to the phantom. The phantom was modeled as a box of water of
unit density. The distance through water along a ray from the ith source to the point of
calculation is given by
ri,w (x, y, z) = ri (x, y, z)

z
SSD

.

(4.27)

From this, the transmission factor is calculated as




TFi,w (x, y, z) = exp −αµ,i µw E 1 (x, y, z) × ri,w (x, y, z)

,

(4.28)


where µw E 1 (x, y, z) is the linear attenuation coefficient for photons of energy E 1 (x, y, z)
in water as calculated via the methods of Sutcliffe [42] . Then, the energy fluence of primary
and leakage photons, ΨP (x, y, z) + ΨL (x, y, z), can be found by applying the transmission
factors (Equations 4.19, 4.26 and 4.28) to the uncollimated energy fluence from Equation
4.13, or
2 Y
2
Y
ΨP (x, y, z)+ΨL (x, y, z) = ΨUC (x, y, z)×TFPC (x, y, z)×
[TFj,k (x, y, z)]×TFw (x, y, z)

.

j=1 k=1

(4.29)
We then convert photon energy fluence to absorbed dose according to

DP (x, y, z) + DL (x, y, z) = (ΨP (x, y, z) + ΨL (x, y, z)) ×
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µen
ρ


,
E 1 (x,y,z)

(4.30)

where (µen /ρ)E 1 (x,y,z) is the photon mass-energy-absorption coefficient in water for photons
of energy equal to the average energy of primary and leakage photons passing through
(x, y, z). As for the linear attenuation coefficients, the mass-energy-absorption coefficient
values for all energies were calculated from a parameterization reported by Sutcliffe [42]. In
the interest of space, the models of head- and patient-scattered dose can be found in ??.
Plugging Equations 4.30, 4.42 and 4.55 into Equation 4.5 yields the total absorbed dose at
the point of calculation, (x, y, z).
4.2.5. Model of Head-Scattered Radiation
The model of head-scattered photon energy fluence comprises two terms, or

ΨHS (x, y, z) = ΨHS,1 (x, y, z) + ΨHS,2 (x, y, z) .

(4.31)

The first head-scatter term is narrower than the second and primarily accounts for the
head-scattered radiation present in and very near to the treatment field. It is defined by

ΨHS,1 (x, y, z) = AHS,1 × CHS (x, y, z) × TFHS,w (x, y, z) ,

(4.32)

where AHS,1 is a field-size dependent scaling factor, CHS (x, y, z) models the lateral extent
of the head-scattered energy fluence, and TFHS,w (x, y, z) models the attenuation of headscattered energy fluence through water.
The amount of head-scattered photon energy fluence reaching the phantom increases
with increasing field area [17, 44]. Thus, the amplitude of the photon energy fluence reaching
the plane of calculation depends on the field-size of interest and was estimated empirically
according to
AHS,1 = κHS,1 × (xs × ys )pHS,1
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,

(4.33)

where κHS,1 is a constant of proportionality; xs and ys are the x- and y-direction field side
lengths, respectively; and the exponent, pHS,1 , governs the dependence of the amplitude on
field size.
The lateral extent of ΨHS,1 (x, y, z) is modeled with cumulative normal functions, or

CHS (x, y, z) =
1− {[1 − cnorm(x, y, z, x1,s (z), σx,HS,1 (z)) + cnorm(x, y, z, x2,s (z), σx,HS,1 (z))]
+ [1 − cnorm(x, y, z, x1,s (z), σx,HS,1 (z)) + cnorm(x, y, z, x2,s (z), σx,HS,1 (z))] (4.34)
× [1 − cnorm(x, y, z, y1,s (z), σy,HS,1 (z)) + cnorm(x, y, z, y2,s (z), σy,HS,1 (z))]}

where x1,s is the distance from the central axis to the field edge in the -x-direction, x2,s is
the distance from the central axis to the field edge in the +x-direction, and y1,s and y2,s
are the same for the y-direction, all projected to the plane of calculation. The penumbral
width is controlled by the width parameters defined as

iso
σx,HS,i (z) = mx,i × (z − ziso ) + σHS
x ,i

,

(4.35)

iso
σy,HS,i (z) = my,i × (z − ziso ) + σHS
y ,i

,

(4.36)

iso
iso
where σHS
and σHS
are the penumbral widths at the depth of isocenter, mx,i and my,i are
x ,i
y ,i

empirical adjustments to the geometric magnification, and i = 1 for the first head-scattered
term. The cumulative normal function is defined in the usual way as

 2

1
1 1
ρ (x, y)
√ ×
√
cnorm(x, y, z, xi,s (z), σ(z)) =
+ erf
2 2
σ(z) 2π
σ(z) 2
where erf denotes the error function.
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,

(4.37)

The second head-scatter term is broader than the first and accounts for the majority
of head-scattered energy fluence outside of the treatment field. It is defined as

ΨHS,2 (x, y, z) = AHS,2 × GHS (x, y, z) × TFHS,w, (x, y, z) × GFHS (x, y, z) ,

(4.38)

where AHS,2 is a field size dependent scaling factor, GHS (x, y, z) models the lateral extent,
TFHS,w, (x, y, z) models attenuation in water, and GFHS (x, y, z) models the increase in
head-scattered fluence out-of-field in regions not covered by the secondary collimators.
As with the first term, the magnitude of ΨHS,2 (x, y, z) varies with field size and is
modeled similarly to Equation 4.33, or

AHS,2 = κHS,2 × (xs × ys )pHS,2

.

(4.39)

The second head-scatter term is modeled as a Gaussian in the x- and y-directions according
to
1
−x2
exp
GHS (x, y, z) =
2
σx,HS,2 (z) × σx,HS,2 (z) × 2π
2σx,HS,2
(z)

!
× exp

−y 2
2
2σy,HS,2
(z)

!
, (4.40)

where σx,HS,2 (z) and σy,HS,2 (z) are as defined in Equations 4.35 and 4.36 for the case i = 2.
In out-of-field regions that are not covered by the secondary collimators (gap regions),
head-scattered radiation must pass through the primary collimator and head-shielding, but
avoids the jaws and multileaf collimator. One might suspect that this reduction in mass
thickness as seen by a ray emanating from the source would result in decreased energy
fluence head-scatter, but the photon energy fluence actually increases in these regions due
to the reduction in self-attenuation of head-scatter in the collimator material. We modeled
this increase in photon energy fluence in the gap regions simply as the ratio of the secondary
collimator transmission factor at the calculation point to the product of the transmission
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factor at the point of calculation. This gap factor is defined as

GFHS (x, y, z) = qHS

TFJaw (x, y, z) × TFMLC (x, y, z)
TFJaw (x, 0, z) × TFMLC (0, y, z)


,

(4.41)

where TFJaw and TFMLC are as defined in Equation 4.26, and qHS is a empirical constant
of proportionality that determines how this ratio translates into increased head-scattered
energy fluence.
Finally, we convert the head-scattered energy fluence as calculated in Equation 4.31
into absorbed dose similarly to Equation 4.30, or

DHS (x, y, z) = ΨHS (x, y, z) ×

µen
ρ


,

(4.42)

E 2 (x,y,z)

where E 2 (x, y, z) is the average energy of head-scattered photons at point (x, y, z) from
Equation 4.1, and (µen /ρ)E 2 (x,y,z) is the mass energy absorption coefficient in water for
photons of energy E 2 (x, y, z) calculated using the methods of Sutcliffe [42].
4.2.6. Model of Patient-Scattered Radiation
Similarly to the head-scattered radiation model, the model of patient-scattered
radiation comprises two terms, or

ΨPS (x, y, z) = ΨPS,1 (x, y, z) + ΨPS,2 (x, y, z) ,

(4.43)

Also, similarly to the head-scattered radiation, the amplitude of the patient-scattered
radiation function depends on the field-area. This was modeled empirically as

APS = κPS × (xs × ys )pPS

,

(4.44)

where κPS is a constant of proportionality and the exponent, pPS , governs the dependence
on field-size.
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Unlike the other components of fluence, patient-scattered radiation is generated
inside the phantom. The build-up of patient scattered energy fluence was modeled according
to
BPS (z) = 1 − exp[−αB × (z − SSD + zB )]

(4.45)

where αB controls the rate at which the patient-scattered energy fluence builds up with depth
in water along the z-axis, and zB is a backscatter factor that prevents the patient-scatter
from falling to zero at the surface. With Equations 4.44 and 4.45 we define the model of
patient-scattered photon energy fluence along the central axis as

ΨPS,cax (z) = APS × BPS (z) × TFPS (0, 0, z)

(4.46)

where TFPS (z) is the transmission factor for patient scattered energy fluence.
Both patient-scatter terms are modeled as Gaussian sources, or
"
#
1
−ρ2 (x, y)
√ × exp
GPS,i (x, y, z) =
(z)
2
2σPS,i
σPS,i (z) 2π

,

(4.47)

where σPS,i (z) is the Gaussian width parameter which is parameterized with depth according
to
surf
σPS,i (z) = kPS,i × (z − SSD) + σPS,i

,

(4.48)

surf
where σPS,i
is the width parameter of the ith patient-scatter source at the surface of the

phantom and kPS,i is an empirical adjustment factor to the geometric magnification.
Again, the first of the two patient-scatter terms is narrower than the second, accounting for the majority of patient-scattered radiation in and near the treatment field. It is
modeled as originating on the central axis at the depth of calculation such that attenuation
is modeled as traveling along a horizontal ray from the central axis to the point of calculation
as in
TFPSw ,1 (x, y) = exp(−αµPS × µPS × ρ(x, y))
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(4.49)

where µPS is the linear attenuation coefficient for patient-scattered photons and αµPS is an
empirical adjustment factor. The complete first term of patient-scattered energy fluence is
then

ΨPS,1 (x, y, z) = cPS × ΨPS,cax (z) × GPS,1 (x, y, z) × TFPSw ,1 (x, y) ×

r(z)
r(x, y, z)

p
(4.50)

where cPS is an empirically determined number between 0 and 1 that apportions the central
axis dose between the first and second patient-scatter terms.
The second patient-scatter term is modeled as originating above the plane of calculation. Though all patient-scattered fluence is generated within the phantom, the amount of
patient-scattered present at a location in the phantom depends on the amount of primary,
leakage, and head-scattered radiation traveling from the treatment head toward the point of
calculation. This in turn depends on the thickness of collimation present along a ray from
the primary photon source to the point of calculation. The influence of collimation on the
patient-scattered energy fluence modeled with cumulative normal functions as in

CPS (x, y, z) = [1 − cnorm(x, y, z, x1,s (z), σPS,2 (z)) + cnorm(x, y, z, x2,s (z), σPS,2 (z))]
+ [cnorm(x, y, z, x1,s (z), σPS,2 (z)) − cnorm(x, y, z, x2,s (z), σPS,2 (z))]

(4.51)

× [1 − cnorm(x, y, z, y1,s (z), σPS,2 (z)) + cnorm(x, y, z, y2,s (z), σPS,2 (z))] .

The transmission factor is then given by

TFPS,col (x, y, z) = CPS (x, y, z)



× −1 + exp −αµcol × µC E 1 (x, y, z) ×

tcol
cos(θ(x, y, z))


(4.52)

where tcol is the averaged thickness of the jaw and multileaf collimator and αµcol is an
empirical correction factor to the mean linear attenuation coefficient of the collimator
material.
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Similarly to the head-scatter model, there is additional fluence present along the
diagonals in regions outside the shadow of the secondary collimators. To model this increase
in fluence, we define a gap factor similar to Equation 4.41 for head-scatter, or

GFPS (x, y, z) = 1 + (αq,PS × FA + βq,PS )



TFJaw (x, y, z) × TFMLC (x, y, z)
−1
×
TFJaw (x, 0, z) × TFMLC (0, y, z)

,

(4.53)

where the coefficient qPS is a constant of proportionality that determines the magnitude
of increase in patient-scattered energy fluence fluence. The complete second term for
patient-scattered energy fluence is then given by

ΨPS,2 (x, y, z) = ΨPS,cax (z) × (1 − cps ) × GPS,2 (x, y, z) ×

r(z)
r(x, y, z)

×GFPS (x, y, z) × TFPS,col (x, y, z) × TFPS (x, y, z)

p
(4.54)
.

Again following the method of Equation 4.30, absorbed dose due to patient-scattered
radiation was calculated as

DPS (x, y, z) = ΨPS (x, y, z) ×

µen
ρ


(4.55)
E 3 (x,y,z)

where ΨPS (x, y, z) is as defined in Equation 4.43. Plugging Equations 4.30, 4.42 and 4.55
into Equation 4.5 yields the total absorbed dose at the point of calculation, (x, y, z).
4.3. Results
4.3.1. Monte Carlo Simulations
The suite of irradiation conditions of the Monte Carlo simulations is detailed in
Table 4.2. Figure 4.7 plots the source energy fluence for the “open field” simulation condition
with all collimators, head-shielding, water, and plastic phantom walls replaced by air. The
tallies of photon energy fluence in the water phantom with all collimators present were
binned by the cell in which the photons were created. Figure 4.8 shows the simulated
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Table 4.2. Conditions for all Monte Carlo simulations performed as part of this work.
Open-field refers to simulations in which all beam-limiting devices have been replaced by
air for the purpose of investigating the uncollimated source fluence.
Phantom

In-Air

In-Water

Field Size
(cm2 )
Open
”
10 ×10
2 ×2
5 ×5
10 ×10
14 ×14
20 ×20
5 ×20
20 ×5

Voxel Size x range
(cm3 )
(cm)
0.125
-50 → 50
1
0 → 40
”
”
1
0 → 40
”
”
”
”
”
”
”
”
”
”
”
”

y range
(cm)
-50 → 50
0 → 40
”
0 → 40
”
”
”
”
”
”

z range
(cm)
50
91.5 → 130.5
”
91.5 → 130.5
”
”
”
”
”
”

Table 4.3. Empirical parameter values for parameterizations average photon energy.
Parameter
Uncollided
n
(N/A)
1
-1
2.58 × 10−2
aE,n (MeV cm )
bE,n (MeV)
−3.98 × 10−1
cE,n (cm-2 )
2.19 × 10−4
dE,n (cm-1 )
−5.83 × 10−2
eE,n (N/A)
4.06 × 100
fn
”
1.00 × 100
σ0,n ”
2.00 × 10−1

Head-Scattered
2
1.44 × 10−2
2.46 × 10−2
−4.23 × 10−4
7.75 × 10−2
−2.90 × 100
1.74 × 100
2.00 × 10−1

Patient-Scattered
3
9.70 × 10−3
−4.25 × 10−1
−1.27 × 10−4
3.04 × 10−2
−1.05 × 100
6.82 × 10−1
2.00 × 10−1

total and component fluences at ziso (depth of 10 cm in the water phantom) for a 6-MV,
10×10-cm2 field. Finally, Figure 4.9 plots the mean photon energy from all components
of photon energy fluence for the 6-MV, 10×10-cm2 field. Values of the empirical fitting
parameters from 4.2–4.4 are listed in Table 4.3.
4.3.2. Analytical Model
4.3.2.1. Photon Source Model
The photon source in-air model parameters are listed in Table 4.6. The model
achieved good agreement with the Monte Carlo simulation of uncollimated source energy
fluence. Quantitatively comparing the uncollimated source model to the simulations, the
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Figure 4.7. Circles represent Monte Carlo simulations of energy fluence from the uncollimated
photon source. The values are normalized to the number of electrons-on-target necessary to
deliver a dose of 1 Gy at dmax . Lines represent the total analytical model of uncollimated
energy fluence and the individual components from the central and lateral source terms.
mean unsigned local relative error,
S ∆Ψ rel ,

US ∆Ψ rel ,

is 9.9%. The mean signed local relative error,

is -0.4%, indicating vanishingly small systematic error. Plots of the uncollimated

source energy fluence, including both the Monte Carlo simulations and analytical model
calculations, are shown in Figure 4.7. Excellent agreement can be seen along the cardinal xand y-axes and in profiles parallel to the axes shifted 20 cm from isocenter.
4.3.2.2. Model of Energy Fluence in a Water-Box
The model of head-scattered radiation in a water-box phantom achieved similarly
good agreement. Figure 4.10 plots head-scattered energy fluence for a 10×10-cm2 field from
Monte Carlo simulations and from the analytical model, revealing excellent agreement in
the x- and y-directions and along the diagonal.
Figure 4.11 shows the Monte Carlo simulated and analytical model calculated patientscattered energy fluence for the 10×10-cm2 field-size at a depth of 5 cm in water. The
dashed and dotted lines represent components of the patient-scattered energy fluence model
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Figure 4.8. Results of Monte Carlo simulation of a 10×10-cm2 collimated photon beam
incident on large water-box phantom, including all components of photon energy fluence.
The values are normalized to the number of electrons-on-target necessary to deliver a dose
of 1 Gy at dmax . Profiles (a) and (b) are at 10 cm depth in water along the x- and y-axes,
respectively. Profile (c) is also at a depth of 10 cm and plots along the line x = y. Plot (d)
shows energy fluence versus depth along the beam’s central-axis.

Figure 4.9. Mean photon energy versus distance from photon-beam central axis at 10-cm
depth in water from a 6-MV, 10×10-cm2 field. Plots include the mean energy of (a) all
photons, (b) primary and leakage photons, (c) head-scattered photons, and (d) patientscattered photons. The solid curves in plots (b)–(d) represent the parameterizations of
mean photon energy defined in 4.1–4.4.
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Figure 4.10. Monte Carlo simulated and analytical model calculated head-scattered energy
fluence for the 10×10-cm2 field-size at a depth of 5 cm in water. The values are normalized
to the number of electrons-on-target necessary to deliver a dose of 1 Gy at dmax .
as given in Equations 4.50 and 4.54, respectively. As in the case of head-scattered radiation,
the top plots in the figure demonstrate agreement in the x- and y-directions. The bottom
right plot reveals good agreement with depth in water including in the build-up region
where Equation 4.45 models the increase of patient-scattered energy fluence with depth.
The model of total energy fluence in water agreed well with the Monte Carlo
simulations. The mean of the unsigned local percent error for all field-sizes and locations
was 10.3%. Figure 4.12 shows a diagonal profile including the Monte Carlo simulated and
analytical model calculated values of energy fluence for all components.
4.3.2.3. Model of Absorbed Dose
All model fitting parameters are listed in Table 4.6. The model of absorbed dose
agreed well with the Monte Carlo simulations. The signed and unsigned average percent
differences were -3.0% and 15.9%, respectively, for all points and field-sizes considered. The
extended gamma index analysis with criteria of 3-mm distance-to-agreement, 3% relative
dose difference in-field, and 3-mGy/Gy absolute dose difference out-of-field resulted in 92.1%
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Figure 4.11. Monte Carlo simulated and analytical model calculated patient-scattered
energy fluence for the 10×10-cm2 field-size at a depth of 5 cm in water. The values are
normalized to the number of electrons-on-target necessary to deliver a dose of 1 Gy at dmax .

Figure 4.12. Monte Carlo simulation (points) and analytical model calculated (lines) photon
energy fluence, including all components, for the case of a 6-MV, 10×10-cm2 field at a depth
of 5 cm in water. The values are normalized to the number of electrons-on-target necessary
to deliver a dose of 1 Gy at dmax .
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Table 4.4. Gamma index passing rates of the analytical model compared with the training
data-set (Monte Carlo). The distance-to-agreement criterion is 3 mm.
∆DA (mGy)
0.5
1.0
3.0
5.0
10.0

1.0%
60.6%
73.5%
81.5%
83.0%
83.8%

∆DR (%)
3.0% 5.0% 7.5% 10.0%
71.2% 74.1% 75.1% 75.4%
84.1% 87.1% 88.0% 88.4%
92.1% 95.1% 96.0% 96.4%
93.6% 96.5% 97.5% 97.8%
94.4% 97.4% 98.3% 98.6%

Table 4.5. Gamma index passing rates of the analytical model compared with the validation
data-set (measurements). The distance-to-agreement criterion is 3 mm.
∆DA (mGy)
0.5
1.0
3.0
5.0
10.0

1.0%
51.3%
68.5%
85.6%
90.7%
92.1%

∆DR (%)
3.0% 5.0% 7.5% 10.0%
53.6% 55.1% 55.4% 55.5%
70.6% 72.1% 72.4% 72.5%
87.8% 89.3% 89.6% 89.7%
92.9% 94.4% 94.7% 94.8%
94.3% 95.7% 96.0% 96.1%

of points passing. The gamma-index passing rates for various criteria are shown in Table 4.4
for all field-sizes and locations. The average wall clock time necessary for the model to
calculate dose to 1 million points was 3 minutes and 19 seconds.
The model also achieved good agreement with measurements (i.e., the validation
data-set). The extended gamma-index analysis of Wilson et al. [45] with criteria of 3-mm
distance-to-agreement, 3% relative dose difference in-field, and 3-mGy/Gy absolute dose
difference out-of-field resulted in 89.3% of points passing. The gamma-index passing rates of
the model compared with the validation data-set for various criteria are shown in Table 4.5.
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Target

B
A

Figure 4.13. 2-dimensional plot of the absorbed dose for a 6-MV 10×10 cm2 field at a
depth of 10 cm in water as calculated by the analytical model. An illustration of the
secondary collimator positioning for a square field has been superimposed above the plot.
Ray A illustrates an example path of a leakage photon that passes through the jaws. Ray
B illustrates an example path of a leakage photon that does not intersect the secondary
collimators.
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Figure 4.14. Absorbed dose to the water-box phantom for case of a 10×10-cm2 field.
Closed circles represent measurements, open circles represent Monte Carlo simulated values,
the solid line represents the analytical model, and the dotted line represents the dose as
calculated by the Computational Environment for Radiotherapy Research (CERR) TPS
[46]. Subplot (a) is a profile at 10-cm depth along the x-axis. Subplot (b) shows dose versus
depth along the photon-beam’s central axis. The dose values are normalized to 1 Gy at
dmax .

Figure 4.15. Absorbed dose to the water-box phantom for case of a 5×5-cm2 field at a
depth of 10 cm. Circles represent Monte Carlo simulated values, the solid line represents
the analytical model calculations, and the dashed and dotted lines represent the Pinnacle
(Philips Healthcare, Andover, MA) and Eclipse (Varian Medical Systems, Inc., Palo Alto,
CA) TPS calculated doses, respectively.
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Table 4.6. Parameter values for analytical model of absorbed dose.
Symbol
Q1
Q2
σ1,0
σ2,0
ρ2,0
αG1
p
aµ,PC,1
aµ,PC,2
aµ,Jaw,1
aµ,Jaw,2
aµ,MLC,1
aµ,MLC,2
aµ,1
aµ,2
κHS,1
pHS,1
iso
σHS,x,1
mx,1

Description
Uncollimated Photon Source In-Air Model Parameters
Electron charge in central source term
Electron charge in each lateral source term
Central source term width parameter
Lateral source terms width parameter
Lateral source Gaussian centroid displacement
Flattening filter build-up parameter
Falloff parameter
Primary and Leakage Dose Model Parameters
Empirical adjustment to PC attenuation for central source term
Empirical adjustment to PC attenuation for lateral source term
Empirical adjustment to jaw attenuation for central source term
Empirical adjustment to jaw attenuation for lateral source term
Empirical adjustment to MLC attenuation for central source term
Empirical adjustment to MLC attenuation for lateral source term
Empirical adjustment to water attenuation for central source term
Empirical adjustment to water attenuation for lateral source term
Head-Scatter Dose Model Parameters
First head-scatter term constant of proportionality
First head-scatter term field-size exponent
First head-scatter term width parameter at isocenter
First head-scatter term width parameter correction to geometric magnification

(table cont’d.)
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Value

Units

2.25 × 10−2
1.93 × 10−2
4.37 × 10−2
1.88 × 10−1
2.05 × 10−1
5.58 × 10−1
1.88 × 100

C
”
cm
”
”
N/A
”

5.56 × 10−1
1.13 × 100
6.48 × 100
8.35 × 100
1.11 × 100
1.40 × 100
8.36 × 10−1
8.98 × 10−1

N/A
”
”
”
”
”
”
”

1.93 × 1010
3.94 × 10−2
8.82 × 10−1
4.50 × 10−1

N/A
”
cm
N/A

Symbol
κHS,2
pHS,2
iso
σHS,x,2
mx,2
iso
σHS,y,2
my,2
αµ,HS
βµ,HS
qHS
κPS
pPS
αB
zB
ασ,PS,1
βσ,PS,1
kPS,1
cPS
ασ,PS,2
βσ,PS,2
kPS2
αq,PS
βq,PS
αµ,PS
βµ,PS
αPC,PS
αcol,PS

Description

Value

Head-Scatter Dose Model Parameters (Continued)
Second head-scatter term constant of proportionality
3.27 × 108
Second head-scatter term field-size exponent
7.77 × 10−2
Second head-scatter term x-width parameter at isocenter
4.24 × 100
Second head-scatter term x-width parameter correction to geometric magnification 6.43 × 100
Second head-scatter term y-width parameter at isocenter
2.48 × 100
Second head-scatter term y-width parameter correction to geometric magnification 9.92 × 100
Empirical adjustment factor for head-scatter attenuation in water
1.19 × 10−1
Empirical adjustment factor for head-scatter attenuation in water
3.15 × 100
Head-scatter gap factor coefficient
3.02 × 10−2
Patient-Scatter Dose Model Parameters
Patient-scatter constant of proportionality
6.30 × 1010
Patient-scatter field-size exponent
4.25 × 10−1
Patient-scatter buildup factor coefficient
2.21 × 10−2
Patient-scatter buildup factor shift
2.90 × 100
st
1 order coefficient for first patient scatter term width parameter
9.50 × 10−1
0th order coefficient for first patient scatter term width parameter
4.10 × 10−8
First patient-scatter term width parameter correction to geometric magnification
6.19 × 10−2
Patient-scatter central-axis apportionment constant
2.19 × 10−1
1st order coefficient for second patient scatter term width parameter
1.63 × 103
th
0 order coefficient for second patient scatter term width parameter
6.18 × 10−2
Second patient-scatter term width parameter correction to geometric magnification 4.36 × 101
1st order coefficient for patient-scatter gap factor constant of proportionality
6.79 × 10−1
0th order coefficient for patient-scatter gap factor constant of proportionality
1.78 × 101
1st order empirical adjustment factor for patient-scatter attenuation in water
1.06 × 100
th
0 order empirical adjustment factor for patient-scatter attenuation in water
8.60 × 10−4
Empirical adjustment factor to primary collimator impact on patient-scatter.
1.25 × 100
Empirical adjustment factor to secondary collimator impact on patient-scatter.
7.40 × 10−1
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Units
”
”
cm
N/A
cm
N/A
”
”
”
N/A
”
”
cm

N/A
N/A

N/A
”
”
”
”

4.4. Discussion
In this work, we developed an analytical model of absorbed dose and photon energy
fluence from primary, leakage, head-scattered, and patient-scattered radiation for 6-MV
X-ray beams. The model realistically calculates transmission through circular MLC leaf
tips and through regions where secondary collimators may overlap or be absent. The major
finding of this work is that it is possible to quickly and accurately calculate the absorbed
dose to arbitrary points in a 3-dimensional phantom from 6-MV photon fields using a
physics based analytical model.
Unlike previous models of this type, this work explicitly models the variation in
absorbed dose both on and off the cardinal axes. Many previous models neglected locations
falling outside of the in- or cross-planes or modeled collimators as semi-infinite planes.
By realistically modeling the 3-dimensional extent of all beam-limiting devices, this work
accounts for the variations in fluence that occur due to the overlapping and absence of
secondary collimators. This increases the domain of applicability of the model and is
necessary if one wishes to accurately calculate out-of-field exposures.
One major strength of this work is the inclusion of a large amount of high-quality
measured data. The measurements were conducted at, and the equipment calibrated by, a
renowned German national standards laboratory. This lends significant confidence to their
accuracy. Another strength is the inclusion of tagged Monte Carlo tallies of each component
of energy fluence and dose (i.e., primary, leakage, head-scattered and patient-scattered
radiation). Jagetic and Newhauser [17] listed uncertainty in the accuracy of the leakage,
head-scatter, and patient-scatter models as a weakness of that work. By verifying the
accuracy of each model component by comparison with Monte Carlo simulations, this work
overcomes that obstacle.
Limitations of this work include the focus on a single model of linear accelerator.
However, this is not a serious limitation because the physics-based nature of the model
should allow users to simply modify the model’s configuration to reflect the dimensions of
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the collimators to match those used in their clinic and train the model on a limited set of
measurements. Access to proprietary information is not required. Another limitation of
this work is the focus on a single photon beam energy. Since 6-MV beams are used in the
majority of treatments, this is not a serious limitation.
Future work related to this project should include expanding the model to the full
suite of clinical beam energies. A detailed, component based model of stray absorbed-dose
necessitates the inclusion of a model of photoneutron absorbed dose. Such work is currently
ongoing in our laboratory. Additionally, the integration of the model into a commercial or
research treatment planning system to test the feasibility of including whole body absorbed
dose calculations into the clinical workflow would be useful to demonstrate feasibility and
utility in a clinical setting
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Chapter 5.
Photoneutron Fluence and Absorbed Dose from 25-MV External
Beam X-Ray Radiotherapy
5.1. Introduction
Neutron contamination is an important component of stray radiation produced by
external beam x-ray treatment units [1, 2]. The main source of neutrons is photoneutron
production induced by photons impinging on high-atomic-number materials in the treatment
unit, such as lead and tungsten. Neutron contamination increases strongly with photon
energy, becoming important at photon beam energies greater than 10 MV. The absorbed
dose (Dn ) to the patient from neutrons is low in comparison with the maximum therapeutic
absorbed dose from the primary field, but the radiation weighting factors for neutrons are
large and vary strongly with energy (2 ≤ wR ≤ 20), and so the neutron contribution to
equivalent dose (Hn ) can be considerable [3, 4]. In spite of this, photoneutron exposures
are neglected by clinical treatment planning systems. The use of high energy beams in
x-ray radiation therapy has increased in recent years due to advantages, such as greater
therapeutic photon dose at depth, reduced photon skin dose, and reduced penumbral dose
due to decreased photon scatter [5, 6], and so the characterization of neutron exposures is
necessary.
Photoneutrons in x-ray radiotherapy are produced primarily through the giant dipole
resonance. Figure 5.1 shows a typical photoneutron spectrum from a 25-MV x-ray beam
at isocenter in air. This illustrates the importance of neutrons produced by evaporation
processes, with a spectral peak between 0.1 and 1 MeV. If water or tissue is present,
this results in a spectrum of neutron energies with three distinct regions, as shown in
Figure 5.2. In Chapter 2, we reported a physics-based analytical model of external neutron
contamination for passively-scattered proton therapy that was based on four neutron energy
regimes, including thermal, 1/E (or epithermal), evaporation, and intranuclear cascade
neutrons [7, 8].
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Figure 5.1. Typical photoneutron energy spectrum, Ψ , at isocenter for a 25-MV beam in
air.
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Figure 5.2. Typical photoneutron energy fluence spectrum, Ψ , at d = 10 cm in water for a
25-MV beam with a source-to-surface distance (SSD) of 90 cm. The small peak located
around 1 MeV is due to evaporation neutrons. The tall peak centered between 10−8 and
10−7 MeV is due to thermal neutrons. Neutrons in the broad continuum between these
peaks are known as 1/E, or epithermal, neutrons. The axis at right shows the neutron
macroscopic cross section in water, Σw , over the same energy interval.
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Table 5.1. Selected measurement conditions for total absorbed dose profiles presented in
this work. The z-direction (depth dose) scans were performed along the central axis of the
photon beam.
Photon Beam Energy
(MV)

Phantom

Field Size
(cm2 )

25

Water

10 × 10

Depth
(cm)
0–40
4, 10

Scan Direction
z
x,y

The literature contains several studies on measurements and empirical models of
neutron exposures [9–13]. Relatively little attention has been paid in the literature to
physics-based analytical models of neutron exposures in radiation therapy, and all such
published works apply to proton therapy [7, 8, 14–17]. It was not known if a comparable
model could be developed for x-ray therapy.
The objective of this work was to develop a new analytical model of absorbed dose
from photoneutrons produced by a 25-MV photon beam incident on a water phantom. The
model was designed and configured based on Monte Carlo simulations of high-energy x-ray
beams delivered by a medical electron linear accelerator. We bench marked the Monte
Carlo model with measurements of total absorbed dose.
5.2. Methods
5.2.1. Measurement of Total Absorbed Dose
The measurement equipment and setup was described elsewhere (Section 4.2.2 [18]).
We measured depth dose and in-plane and cross-plane half-profiles listed in Table 5.1.
5.2.2. Monte Carlo Simulations
Simulations were performed using the Monte Carlo N-Particle eXtended (MCNPX)
transport code (version 2.7) [19]. The dimensions and material definitions of the linac
(Precise Treatment SystemTM , SN 151617, Elekta, Stockholm, Sweden) were taken from
proprietary information provided by the manufacturer [20]. The geometry of the model is
as described in Section 4.2.3 except that the 6-MV flattening filter has been replaced by the
two component 25-MV flattening filter system, as illustrated in Figure 5.3. All simulations
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Figure 5.3. Cross-sectional schematic diagram of the linac head illustrating the relative
locations of the beam-modifying and beam-limiting devices including the X-ray target, the
cylindrical primary collimator, the flattening filter, the monitor chamber, the multi-leaf
collimators (MLCs), jaws, and head-shielding. The location of the jaw is rendered with a
dotted line since it may not intersect the yz-plane for a given field. Note: Dimensions are
not to scale.
Table 5.2. Neutron energy regime definitions and number of energy bins in each regime. En
refers to neutron energy.
Energy Regime
Thermal
1/E (Epithermal)
Evaporation

Definition
En < 3 × 10−7 MeV
−7
3 × 10 MeV ≤ En ≤ 3 × 10−2 MeV
En > 3 × 10−2 MeV

# of Bins in Regime
13
25
15

were configured to transport neutrons, photons, and electrons (mode n p e). F6-type energy
deposition tallies were performed for neutron, protons, and electrons, and summed to yield
the total absorbed dose at each tally location. F4-type tallies of neutron spectral fluence
were binned uniformly in log(En ) between 10−9 and 25 MeV. We divided the fluence into
three energy regimes. The energy regime definitions and number of energy bins in each
regime are list in Table 5.2.
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The dose deposited by neutrons in the ith energy bin was calculated with with kerma
factors obtained from Chadwick et al. [21] as

CPE

Dn,i = Kn,i = kφ,i × φn,i

,

(5.1)

where Kn,i is the kerma due to neutrons in the ith energy bin, kφ,i is the kerma coefficient
for neutrons in the ith energy bin, and φn,i is the neutron fluence in the ith energy bin. The
assumption of charged particle equilibrium is justified as results in the literature have shown
dmax,n (i.e., the depth of maximum neutron dose), to be at or shallower than 4 cm, the
shallowest depth for which we calculated dose [22, 23].
We calculated neutron equivalent dose, (Hn ), according to

Hn,i = wR (Ei ) × Dn,i

.

(5.2)

The radiation weighting factors, wR (Ei ), were calculated according to the formula from
ICRP Publication 92 [24], or




−ln(En )2
−ln(En /30)2
wR (En ) = 2.5× 2 − exp(−4En ) + 6 × exp
+ exp
4
2


. (5.3)

We verified the accuracy of the Monte Carlo simulations by benchmarking the
simulated total absorbed dose against the corresponding measured values at the same
locations. The local relative difference in dose at the q th point is

∆D i =

DMC,q − Dm , q
× 100% ,
Dm,q
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(5.4)

where DMC,i is the Monte Carlo simulated dose at the q th location, and Dm,q is the corresponding measured value. We then calculated the mean unsigned dose difference according
to
∆D =

Np
X


abs

q=1

∆D q
Np


,

(5.5)

where Np is the number of points.
From the Monte Carlo data, we also determined the fluence weighted average
macroscopic neutron interaction cross section, neutron mean free path, and neutron kerma
coefficient for the three neutron energy regimes considered. The average macroscopic neutron
interaction cross section of the j th neutron energy regime, Σ j , was calculated according to

Σj =

n
X
Σ (Ei ) × φ(i)

,

Φj

i=1

(5.6)

where Φj is the total fluence of the j th energy regime, Σ (Ei ) is the ENDF-VII/B macroscopic
cross section for neutrons of energy Ei in water, and φi is the fluence of neutrons in
theith energy bin. The neutron mean free path, also known as the relaxation length, was
calculated simply as
λj =

1
Σj

.

(5.7)

Finally, the fluence weighted average kerma factor of the j th energy regime was calculated
by
kφ,j =

n
X
kφ,i × φi
i=1

Φj

.

(5.8)

5.2.3. Analytical Model
The analytical model for neutron fluence in the j th energy regime at a point, p, in
the phantom is

Φj,p = Cj × Φiso

r
ziso

−qj

 2 2 


−ρ ziso
0
0
exp −αj Σ j (r − ziso ) exp
× Mj,p
2σj2 z 2
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,

(5.9)

where Φiso is the total neutron fluence at isocenter obtained from the Monte Carlo data,
r = x2 + y 2 + z 2 is the distance from the neutron source to the point of calculation, ziso is
the distance from the neutron source to isocenter, q is an exponent governing geometric
divergence of the neutron field, Σ j is the mean macroscopic neutron interaction cross section
(Equation 5.6), αj is an empirical adjustment factor to the macroscopic cross section, r0 is
0
the distance through water from the source to the point of calculation, ziso
is the depth of

isocenter, ρ2 = x2 + y 2 for the point of calculation, σj is the width parameter governing
the lateral falloff, the Cj factors apportion the fraction of fluence at isocenter to each of
P
the three energy regimes such that 3j=1 Cj = 1, and Mj,p is function that corrects for the
moderation of j th energy group neutrons out-of-field by the beam-limiting devices in the
treatment head. We define j = 1 to represent the thermal neutron regime, j = 2 for the
epithermal neutron regime, and j = 3 for the evaporation neutron regime. The relevant
distances are labeled in Figure 2.1.
The beam-limiting devices in the treatment head are composed of poor neutron
moderators such as tungsten and lead. However, their effect on neutron fluence is not
negligible. The attenuation of neutron fluence in the j th energy group is modeled with a
cumulative distribution function, or


ρ−µM,j
√
1 − erf σ
M,j 2

+ (1 − bM,j ) × 
2


Mj,p = bM,j

,

(5.10)

where µM,j is the normal distribution mean, σM,j is the width parameter, bM,j is a constant,
and “erf” is the error function.
The absorbed dose at a point, p, is modeled as the sum of the three fluence regimes
each multiplied by its corresponding mean kerma coefficient, or

Dp =

3
X

kφ,j × Φj,p

j=1
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Figure 5.4. Measured and simulated dose (D) versus depth (z) of a 25-MV photon beam
with a field size of 10×10 cm2 along the beam’s central axis in water. Note: The measured
curve begins at d = 4 cm. This is because the thickness of the phantom wall and the size of
the detector prevented shallow measurements.
where kφ,j is the average kerma factor as defined in Equation 5.8, and Φj,p is the total
fluence in the j th neutron energy regime at the point of calculation, p.
5.3. Results
The values of total absorbed dose obtained from the Monte Carlo simulations agreed
well with the corresponding measured values. The mean local relative dose difference, ∆D,
was found to be 9.9% for all locations considered. Figure 5.4 shows plots of the depth dose
measured and simulated along the beam’s central axis. Figures 5.5 and 5.6 show half-profiles
of the measured and simulated absorbed doses in the x- and y-directions, respectively, for
depths of 4, 10, 20, and 40 cm.
Figure 5.7 shows a half-profile plot of the analytical model of neutron fluence along
with the Monte Carlo values. The model parameters from Equation 5.9 are listed in
Table 5.3. The average local relative difference between the analytical model and the Monte
Carlo data for absorbed dose from neutrons was found to be 6.8%.
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Figure 5.5. Measured and simulated absorbed dose (D) versus lateral position (x) of a
25-MV, 10×10 cm2 photon beam at four depths in water. The markers indicate the Monte
Carlo simulation values, and the lines show the measured doses. Each curve was normalized
to the measured dose at isocenter. The upper three curves were offset by an order of
magnitude each for visibility.

Figure 5.6. Measured and simulated absorbed dose (D) versus lateral position (y) of a
25-MV, 10×10 cm2 photon beam at four depths in water. The markers indicate the Monte
Carlo simulation values, and the lines show the measured doses. Each curve was normalized
to the measured dose at isocenter. The upper three curves were offset by an order of
magnitude each for visibility.
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Figure 5.7. Half-profile of neutron fluence, Φn , predicted by Monte Carlo and analytical
model. Plot is for a 25-MV, 10×10 cm2 x-ray field at a depth of 4 cm in a water-box
phantom. Error bars indicate the standard error of the Monte Carlo tallies.

Figure 5.8. Half-profile of neutron absorbed dose, Dn , predicted by Monte Carlo and
analytical model, including individual energy groups. Plot is for a 25-MV, 10×10 cm2 x-ray
field at a depth of 4 cm in a water-box phantom. Error bars indicate the standard error of
the Monte Carlo tallies.
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Figure 5.9. Log scale plot showing half-profile of of neutron absorbed dose, Dn , predicted by
Monte Carlo and analytical model, including individual energy groups. Plot is for a 25-MV,
10×10 cm2 x-ray field at a depth of 4 cm in a water-box phantom. Error bars indicate the
standard error of the Monte Carlo tallies.

Table 5.3. Model inputs calculated from Monte Carlo data, and model fitting parameters.
Symbol
Φiso
C1
C2
C3
Σ1
Σ2
Σ3
kφ,1
kφ,2
kφ,3

Calculated Inputs
Value
Units
6
7.45 × 10
cm−2
0.60
N/A
0.24
N/A
0.16
N/A
0.69
cm−1
0.50
cm−1
0.20
cm−1
1.6 × 10−16
Gy cm2
2.5 × 10−13
Gy cm2
−11
2.0 × 10
Gy cm2

Symbol
ziso
σ1
σ2
σ3
α1
α2
α3
q1
q2
q3
µM,1
µM,2
µM,3
σM,1
σM,2
σM,3
bM,1
bM,2
bM,3
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Fitting Parameters
Value
Units
84.6
cm
60.6
cm
9.78
cm
4.65
cm
0.29
N/A
0.10
N/A
0.71
N/A
0.10
N/A
1.01
N/A
0.99
N/A
3.92
cm
3.73
cm
6.57
cm
1.04
cm
1.15
cm
1.20
cm
0.92
N/A
0.84
N/A
0.62
N/A

5.4. Discussion
In this work we developed a new analytical model of absorbed dose from neutron
contamination in a 25-MV photon beam. To configure the model, we performed Monte Carlo
simulations of neutron fluence and total absorbed dose, and we performed measurements
of the total absorbed dose both in- and out-of-field in order to validate the Monte Carlo
simulations. The major finding of this work is that it appears to be feasible to calculate
the neutron dose, Dn (x, y, z), with a fast and accurate analytical model suitable for use in
the clinical workflow, which is not current achievable with measurements or Monte Carlo
simulations. This has implications for radiotherapy treatment planning, clinical decision
making, and for retrospective studies of the effects of neutron exposures to radiation therapy
patients.
Strengths of this study include the novelty of modeling the photoneutron absorbed
dose from three neutron energy regimes. This is similar to the approach our laboratory has
taken in modeling neutron dose in proton therapy treatments [7, 8]. To our knowledge, no
other work has applied this approach to photoneutron modeling in x-ray radiation therapy.
We separately modeled neutron absorbed dose and neutron weighting factors to facilitate
the use of other energy dependent radiation weight factors and dose-response models that
may supersede ICRP Publication 92 in the future.
Limitations of this work include that we only considered 25-MV x-ray beams. This
is the highest x-ray beam energy routinely used in clinics and is, thus, the beam energy for
which the photoneutron hazard is greatest. Work is on going in our laboratory to extend
this model to the full interval of clinically relevant photon beam energies. Another limitation
is the lack of measured neutron absorbed doses to validate the model. This is not a serious
limitation because we partially validated our Monte Carlo model against measurements of
total absorbed dose, and previous studies have shown the Monte Carlo software package we
used to be reliable for calculating photoneutron exposures [9, 23].
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Chapter 6.
External and Internal Neutron Absorbed Dose from Proton Radiotherapy
6.1. Introduction
Proton therapy has been found to achieve desired tumor volume coverage with lower
dose to a patient’s healthy tissues in many cases compared with other forms of radiation
therapy [1–3]. Some stray radiation exposure, however, is unavoidable [4, 5]. In proton
therapy, the dominant source of stray radiation is neutron contamination. Stray neutrons
are primarily produced by nuclear reactions between primary protons and atomic nuclei in
the treatment head as well as in the patient or phantom [6]. Neutrons emanating from the
treatment head are referred to as external or leakage neutrons. Neutrons produced in the
patient are referred to as internal or patient-scattered neutrons.
Previous works from our laboratory have reported on Monte Carlo and analytical
models of external neutron exposures from passively-scattered proton therapy (PSPT) [7–9].
In this work, we report on simulations of external and internal neutron exposures from a
compact commercial proton therapy system.
6.2. Methods
The PSPT Monte Carlo simulations were conducted with a model of the proton
therapy gantry beamline at the Centre de Protonthérapie de l’Institut Curie in Orsay,
France. The clinic is a three room proton therapy center that operates two fixed beamlines,
in addition to the gantry beamline, based on the Proteus Plus system (IBA, Louvain-LaNeuve, Belgium). Simulations were performed using the Monte Carlo N-Particle eXtended
(MCNPX) code version 2.7 [10] for proton beam energies of 162, 192, 207, and 219 MeV.
These energies were chosen to coincide with those from a previous work [11]. The field
simulated was circular with a diameter of 5.5 cm. We exploited this radial symmetry by
simulating a 1-m diameter cylindrical water phantom.
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Treatment
Head
Phantom

Stopping
Plane

Figure 6.1. Monte Carlo simulation vault geometry. The inset shows a magnified view of
the treatment head and phantom.
The Monte Carlo geometry consisted of the treatment vault and proton therapy
treatment head setup for the the passive-scattering technique. Figure 6.1 shows a plot of the
vault geometry and a close up view of the treatment head, voxelized water phantom, and
the location of the stopping plane. The stopping plane was used alternatively to stop either
external neutrons (imp:n=0, imp:h=1) or to stop primary protons (imp:n=1, imp:h=0) in
order to discriminate between the dose from external and internal neutrons. Simulations
were also run with the no particles stopped in the plane (imp:n=1, imp:h=1) in order to
tally the total dose from protons and neutrons. Tallies of neutron fluence were binned
logarithmically in energy with 40 energy bins per decade.
The phantom was voxelized in cylindrical coordinates with the off-axis distance
denoted ρ, depth in water denoted d, and azimuthal angle denoted ϕ. The step sizes for
voxelization were δd = 1 cm, δϕ = π/4 radians, and δρ = 1 cm for ρ < 28 cm and δρ = 2
cm for ρ = 28 cm to 50 cm. This yields a total of 6.4×104 voxels. All simulation results
were normalized per 109 primary protons.
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Figure 6.2. Spectral neutron energy fluence, Ψn , on central axis at 10-cm depth in water for
all proton beam energies considered.
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Figure 6.3. Spectral neutron energy fluence, Ψn , 10 cm off-axis at 10-cm depth in water for
all proton beam energies considered.
6.3. Results
The neutron spectral energy fluence is shown at 10-cm depth in water along the
central axis for all proton beam energies considered in Figure 6.2. Figure 6.3 shows the
same at an off-axis distance of ρ = 10 cm. The spectral energy fluence from all neutrons,
only external neutrons, and only internal neutrons are plotted in Figure 6.4 for the 219-MeV
beam at ρ = 0 cm and d = 10 cm. Figure 6.5 shows the corresponding data at 10 cm
off-axis.
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Figure 6.4. Spectral neutron energy fluence, Ψn , from all neutrons, external neutrons, and
internal neutrons on central axis at 10-cm depth in water for the 219-MeV proton beam.
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Figure 6.5. Spectral neutron energy fluence, Ψn , from all neutrons, external neutrons, and
internal neutrons 10-cm off-axis at 10-cm depth in water for the 219-MeV proton beam.
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Figure 6.6. Neutron absorbed dose, Dn , along the proton beam’s central axis for several
proton beam energies.
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Figure 6.7. Neutron absorbed dose, Dn , from all neutrons, external neutrons, and internal
neutrons along the proton beam’s central axis for the 219-MeV beam.
Absorbed dose from neutrons along central axis is shown for three beam energies in
Figure 6.6. Figure 6.7 shows a breakdown of the total, external, and internal neutron dose
along central axis for the 219-MeV beam.
Figure 6.8 shows a half profile of the total absorbed dose, along with the proton and
neutron doses, from the 219-MeV beam at a depth of 10 cm in water. In this plot, the dose
from internal neutrons is greater than that of external neutrons in the in-field and near-field
regions. Linearly interpolated estimations of the off-axis distance at which the dose from
external neutrons equals that of internal neutrons are listed in Table 6.1 for different proton
beam energies and depths in water.
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Figure 6.8. Total absorbed dose, D, for the 219-MeV beam versus off-axis distance, ρ, at a
depth of 10 cm in water. Also shown are the absorbed doses from protons, the dose from
all neutrons, and the dose from external and internal neutrons, respectively.

Table 6.1. Off-axis distances, ρ, at which absorbed dose from external neutrons overtakes
that of internal neutrons for three proton beam energies and depths in water. Also listed
are the distances, δ, from the field edge at which external neutron dose overtakes that of
internal neutrons, with positive values indicating that the transition takes place outside of
the primary treatment field.
Depth (cm)
5
10
20

192 MeV
ρ (cm) δ (cm)
2.71
0.21
4.13
1.63
5.47
2.97

207 MeV
ρ (cm) δ (cm)
2.29
-0.21
3.97
1.47
6.20
3.70
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219 MeV
ρ (cm) δ (cm)
1.44
-1.06
3.59
1.09
5.90
3.40

6.4. Discussion
In this work, we performed Monte Carlo simulations of the neutron fluence and
proton and neutron absorbed dose from a modern, compact proton therapy system. We
segregated the neutron energy fluence and absorbed dose from external neutrons (produced
in the treatment head) and internal neutrons (produced in the phantom). We also estimated
the off-axis distance at which the dose from external neutrons becomes greater than that
from internal neutrons.
The results of this work show that the absorbed dose from internal neutrons may
be greater than that of external neutrons both in and near the primary treatment field.
The distance beyond the field-edge at which external neutron dose surpasses the internal
neutron dose increases with increasing depth in the phantom and does not appear to depend
strongly on the proton beam energy. This is an important finding because the region in the
periphery of the primary treatment field exhibits the greatest risk per volume for radiation
late effects such as second cancers. Attempts to estimate such risks while considering only
external neutron doses may lead to underestimations.
Strengths of this study include the use a Monte Carlo model based on design drawings
from a modern proton therapy facility and the inclusion of multiple clinically relevant beam
energies. Additionally, the use a radially symmetric computational phantom with voxels
based in cylindrical coordinates resulted in excellent simulation statistics even far from the
primary field, making this simulated data potentially useful for the design and configuration
of analytical models of external and internal neutron dose. Limitations of this study include
the use of only a single field size and the lack of simulated irradiations on any heterogeneous
phantom. Future work should include the addition of multiple field sizes including irregularly
shaped fields.
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Chapter 7.
Conclusion
This work reports several related advancements in characterizing stray radiation dose
from radiotherapy. In Chapter 2, we reported a new analytical model to predict leakage
neutron exposures from proton therapy. In Chapters 3 and 4 we presented new analytical
models of absorbed dose from primary and stray photons in megavoltage x-ray radiation
therapy. To develop, configure, and test the models, we made in-field and out-of-field dose
measurements. In order to accurately predict the out-of-field photon exposures, it was
necessary to model the geometry of the collimators in greater detail than was previously
attempted in the literature. In Chapter 5, we reported a model of photoneutron absorbed
dose from 25-MV x-ray radiotherapy. Finally, in Chapter 6, we report a Monte Carlo model
of external and internal neutron energy fluence and absorbed dose from a modern, compact
proton therapy system.
7.1. Implications
The works presented in this dissertation suggest that it is feasible to calculate the
radiation exposure due to primary and stray radiation from megavoltage x-ray radiation
therapy and proton therapy. The results revealed strong variation in the absorbed dose
out-of-field, suggesting that personalized exposure assessments will be needed.
The results of this work may find applications in clinical tools to prospectively
provide such information for radiotherapy patients. This would be useful for enabling the
direct optimization of radiotherapy patient health outcomes [1]. Radiation epidemiology
studies often must retrospectively reconstruct exposures to large numbers of patients with
limited dosimetric data available from the original treatment plan. The reported analytical
models could be used to accomplish such a task. Other applications include estimating
doses to late-responding tissues in cases of re-irradiation [2, 3], estimating the photon and
neutron dose to radiosensitive medical implants such as pacemakers [4], and estimating the
dose to the fetus in the case of a pregnant radiotherapy patient [5–7].
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7.2. Coherence with the Literature
The models reported in this dissertation exhibit generally good agreement with others
found in the literature. However, direct comparisons of our reported models with published
literature were not possible for some previous studies. Many works describing analytical
models of stray radiation dose are only applicable for specific treatment machines and
techniques. Furthermore, most previous reports of analytical models of stray radiation are
not reproducible because they neglected to report model parameter values, model equations,
and other information necessary to replicate the results. For models of secondary neutron
exposures, an additional obstacle is that not all attempts at modeling have focused on the
same quantity of radiation exposure, with some researchers choosing to model equivalent
dose and others absorbed dose. That said, the equivalent dose predictions of our model of
leakage neutron exposure from passively-scattered proton therapy reported in Chapter 2
agree with those predicted by Perez-Andujar et al. [8] within 9%.
The previously published work that is most directly comparable to the photon models
reported in this dissertation is that of Jagetic and Newhauser [9], which reported an absorbed
dose model for 6-MV photons applicable at depths of 1.5 and 10 cm for off-axis distances
of 0–40 cm in the in- and cross-plane directions. The total absorbed doses predicted for
these conditions by the simplified photon absorbed dose model from Chapter 3 and the
physics-based photon absorbed dose model from Chapter 4 of this work each agree with the
doses predicted by Jagetic and Newhauser within 10%. While the total doses do agree well,
the proportions of leakage, head-scatter, and patient-scatter dose reported in Chapter 4
differ from those reported by Jagetic and Newhauser. This is not a concern, because the
model components reported in this work were developed and configured based on more
measured data and on benchmarked Monte Carlo simulations of leakage, head-scatter, and
patient-scattered radiation.
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Direct comparisons of the measurements performed in this dissertation with those
from the literature are difficult because the stray radiation exposures from different models
of treatment machines vary by an order of magnitude [10]. However, the models reported
in Chapters 2 and 3 were based partially on previously published Monte Carlo data and
measurements from Perez-Andujar et al. [8] and Halg et al. [11], and agreed with both
previously published and original data. Additionally, the measured out-of-field photon doses
produced for this dissertation qualitatively agree with previously reported measurements
including Stovall et al. [5], Kase et al. [12], and Kaderka et al. [13]. These works reported
that the dose can be roughly described as falling off quasi-exponentially with distance from
the field-edge, although this dissertation included more measurement locations than the
previous works and is the only such work to consider points lying outside of the in- and
cross-planes.
7.3. Future Work
The long-term goal of this work is to improve the health outcomes of radiotherapy
patients by providing the clinical and research tools necessary to reduce the risk of radiation
late effects. Some additional research will be required before this can be fully realized.
Future work should include the independent implementation of the models presented to
ensure reproducibility. The technical feasibility of integrating these models in commercial
treatment planning systems should also be studied. The model presented in Chapter 2 was
implemented into a research treatment planning system by Eley et al. [14]. This model was
also independently implemented by Gallagher and Taddei [15].
This dissertation examined externally produced secondary neutron doses from collimated passively-scattered proton beams and the internally (i.e., within the patient) produced
secondary neutrons. However, proton therapy treatments delivered via pencil-beam scanning with the addition of collimators to improve penumbral widths are becoming more
common, and so it is necessary to investigate the external neutron production from pencil
beam treatments delivered with collimators such as proton mini-beam treatments [16–18].
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Additionally, the compact, cyclotron based proton therapy units in use at many new proton
centers adjust the proton-beam energy via the use of low-Z range-shifter slabs located in
the treatment head [19]. The use of energy degraders in close proximity to the patient will
also result in increased neutron exposure that should be characterized.
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